Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Di Virgilio, F.
Right arrow Articles by Baricordi, O. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Di Virgilio, F.
Right arrow Articles by Baricordi, O. R.
Related Collections
Right arrow Hemostasis, Thrombosis, and Vascular Biology
Right arrow Review Articles
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, 1 February 2001, Vol. 97, No. 3, pp. 587-600

REVIEW ARTICLE

Nucleotide receptors: an emerging family of regulatory molecules in blood cells

Francesco Di Virgilio, Paola Chiozzi, Davide Ferrari, Simonetta Falzoni, Juana M. Sanz, Anna Morelli, Maurizia Torboli, Giorgio Bolognesi, and O. Roberto Baricordi

From the Department of Experimental and Diagnostic Medicine, Section of General Pathology and Medical Genetics, and Center of Biotechnology, University of Ferrara, Ferrara, Italy.


    Abstract
Top
Abstract
Introduction
P2 receptors: what are...
P2Y receptors
P2X receptors
P2 receptors in...
P2Y and P2X subtype...
Role of P2 receptors...
P2 receptors in dendritic...
P2 receptors in lymphocytes
P2 receptors in...
P2 receptors in platelets
P2 receptors in erythrocytes
P2 receptors on bone...
Conclusions
References

Nucleotides are emerging as an ubiquitous family of extracellular signaling molecules. It has been known for many years that adenosine diphosphate is a potent platelet aggregating factor, but it is now clear that virtually every circulating cell is responsive to nucleotides. Effects as different as proliferation or differentiation, chemotaxis, release of cytokines or lysosomal constituents, and generation of reactive oxygen or nitrogen species are elicited upon stimulation of blood cells with extracellular adenosine triphosphate (ATP). These effects are mediated through a specific class of plasma membrane receptors called purinergic P2 receptors that, according to the molecular structure, are further subdivided into 2 subfamilies: P2Y and P2X. ATP and possibly other nucleotides are released from damaged cells or secreted via nonlytic mechanisms. Thus, during inflammation or vascular damage, nucleotides may provide an important mechanism involved in the activation of leukocytes and platelets. However, the cell physiology of these receptors is still at its dawn, and the precise function of the multiple P2X and P2Y receptor subtypes remains to be understood. (Blood. 2001;97:587-600)

© 2001 by The American Society of Hematology.

    Introduction
Top
Abstract
Introduction
P2 receptors: what are...
P2Y receptors
P2X receptors
P2 receptors in...
P2Y and P2X subtype...
Role of P2 receptors...
P2 receptors in dendritic...
P2 receptors in lymphocytes
P2 receptors in...
P2 receptors in platelets
P2 receptors in erythrocytes
P2 receptors on bone...
Conclusions
References

In 1978 the existence of plasma membrane receptors for extracellular nucleotides, the P2 purinergic receptors, was formally recognized.1 At that time, this identification was only based on pharmacologic and functional evidence and on the prophetic intuition of Geoff Burnstock. To date, 12 mammalian P2 receptors have been cloned, characterized, and recognized as responsible for the diverse cellular responses to stimulation with extracellular nucleotides.2,3 The P2 receptor family also includes receptors for extracellular pyrimidines. The new classification based on the molecular structure is rapidly replacing the previous one (P2Y, P2X, P2U, P2T, and P2Z) based on the pharmacologic profile,4 although doubts remain on whether functional responses of the native P2Z receptor of immune cells can be entirely explained by the cloned P2X7 subunit. A similar uncertainty also concerns the platelet P2T receptor, which is likely to arise from the combination of P2Y and P2X-dependent responses.2,5 Extracellular effects of nucleotides were initially recognized in smooth muscle contraction, neurotransmission, regulation of cardiac function, and platelet aggregation.6 However, over the last 10 years it has become clear that the intercellular mediator role of these molecules is widespread, and blood cells have emerged as one of the most interesting targets.

Contrary to a widely held opinion, adenosine triphosphate (ATP) and possibly also uridine triphosphate (UTP) are often released into the extracellular environment via nonlytic mechanisms7-12 and also more frequently as a consequence of cell damage or acute cell death. Furthermore, platelet-dense granules are a relevant source of secreted ATP.13,14 Once in the pericellular environment, ATP can serve as a ligand for P2 receptors or be quickly hydrolyzed by powerful ubiquitous ecto-ATPases and ectonucleotidases.15-18 ATP can also be used as a phosphate donor by poorly characterized ectokinases.19 Thus, ATP possesses all the properties of a bona fide fast-acting intercellular messenger: (a) it is released in a controlled fashion, (b) ligates specific plasma membrane receptors coupled to intracellular signal transduction, and (c) is quickly degraded to terminate its action.

Outside excitable tissues, P2 receptors have an obvious relevance in platelet aggregation, but immunity and inflammation are providing some of the most exciting developments in this evolving field. A few reviews covering different aspects of P2 receptor distribution and function in hemopoietic cells have appeared and have been an invaluable source of information for the present work.20-26


    P2 receptors: what are they?
Top
Abstract
Introduction
P2 receptors: what are...
P2Y receptors
P2X receptors
P2 receptors in...
P2Y and P2X subtype...
Role of P2 receptors...
P2 receptors in dendritic...
P2 receptors in lymphocytes
P2 receptors in...
P2 receptors in platelets
P2 receptors in erythrocytes
P2 receptors on bone...
Conclusions
References

According to the International Union of Pharmacology (IUPHAR) Committee on Receptor Nomenclature and Drug Classification,27 receptors for extracellular nucleotides are termed P2 receptors (this nomenclature replaces the older "P2-purinoceptor"). P2 receptors are divided into 2 subfamilies: G protein-coupled (P2Y) and ligand-gated ion channels (P2X).3,28-30 Current P2Y/P2X nomenclature is based on the molecular structure and has replaced the previous one based on pharmacologic and functional criteria. In mammalian cells, 5 P2Y (P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11) and 7 P2X (P2X1-7) receptors have been cloned and characterized pharmacologically2 (Table 1). P2Y5, P2Y7, P2Y9, and P2Y10 have been purged from this sequence because they are primarily non-nucleotide receptors (although they may also bind extracellular nucleotides). A p2y3 (lower case to indicate that it has not been cloned from mammals) receptor has been cloned from chick brain and suggested to be a homologue of the mammalian P2Y6.2 P2Y8 has so far only been cloned from Xenopus neural plate; thus it is not included in the list of mammalian receptors. The adenosine diphosphate (ADP)-activated, G protein-coupled receptor of platelets that triggers inhibition of stimulated adenylate cyclase has not yet been cloned; thus it is recommended that this receptor should be given in italics: P2Y ADP.2

                              
View this table:
[in this window]
[in a new window]
 
Table 1. P2Y and P2X receptor subtypes


    P2Y receptors
Top
Abstract
Introduction
P2 receptors: what are...
P2Y receptors
P2X receptors
P2 receptors in...
P2Y and P2X subtype...
Role of P2 receptors...
P2 receptors in dendritic...
P2 receptors in lymphocytes
P2 receptors in...
P2 receptors in platelets
P2 receptors in erythrocytes
P2 receptors on bone...
Conclusions
References

P2Y receptors are 7-membrane-spanning proteins, numbering from 328 to 379 amino acids, for a molecular mass of 41 to 53 kd after glycosylation.2,31,32 The aminoterminal domain faces the extracellular environment, and the carboxyterminal is on the cytoplasmic side of the plasma membrane (Figure 1). Signal transduction occurs via the classical pathways triggered by most 7-membrane-spanning receptors: activation of phospholipase C and/or stimulation/inhibition of adenylate cyclase. All of the P2Y receptors are activated by ATP, but at 2 of them, P2Y4 and P2Y6, UTP is more potent,33-36 and at P2Y2 ATP and UTP are equipotent.31 At P2Y1, UTP is inactive and ADP is reported to be equipotent or even more potent than ATP37,38; at P2Y11 ATP is more potent than ADP and UTP is inactive.39 With respect to the signal transduction pathway, P2Y1 and P2Y2 are coupled to stimulation of phospholipase C-beta and inhibition of adenylate cyclase via Gq/11 and Gi proteins, respectively.2 There are reports suggesting that P2Y2 can also trigger stimulation of phospholipase D and breakdown of phosphatidylcholine, but the mechanism is unclear.40 P2Y4 and P2Y6 seem to only couple to phosphoinositide breakdown, whereas P2Y11 rather surprisingly stimulates activation of both the phosphoinositide and the adenylate cyclase pathways.


View larger version (32K):
[in this window]
[in a new window]
 
Figure 1. Membrane topology of P2Y and P2X receptor subunits. (A) P2Y receptors (i) are typical 7-membrane-spanning receptors made of a single polypeptide chain, with the N- and C-termini on the external and cytoplasmic side of the plasma membrane, respectively. P2X receptors (ii) are formed by subunits that span the plasma membrane twice and have both the N- and C-termini on the cytoplasmic side. The P2X7 subunit differs from the other members of the P2X subfamily (P2X1-P2X6) in the extended carboxyterminal tail (iii). (B) It is hypothesized that P2X7 receptor is generated by the aggregation of an unknown number of subunits (maybe 6) to form an ATP-activated channel. Recruitment of additional subunits causes formation of a nonselective pore (also see Figure 2).

Investigation of P2Y receptors has been severely hindered by the lack of specific antibodies, whether polyclonal or monoclonal. Likewise, few selective agonists, besides naturally occurring nucleotides, or antagonists are available. A widely used P2Y antagonist is suramin,41 a drug originally developed for the treatment of tripanosomiasis. However, suramin does not discriminate between P2Y and P2X and has been reported to inhibit other receptors such as the nicotinic, glutamate, GABA, and 5-hydroxytryptamine receptors as well as the activity of diverse growth factors.2 Reactive blue 2, trypan blue, and reactive red have also been used as P2Y antagonists, but they also block P2X-dependent responses.2 Recently Harden and coworkers have introduced a number of nucleotide analogues as competitive P2Y1 antagonists.42,43 Pyridoxal phosphate (P5P) and pyridoxalphosphate-6-azophenyl 2',4'-disulfonic acid (PPADS) are also sometimes used to inhibit P2Y-dependent responses, but they are more widely employed to block P2X receptors.


    P2X receptors
Top
Abstract
Introduction
P2 receptors: what are...
P2Y receptors
P2X receptors
P2 receptors in...
P2Y and P2X subtype...
Role of P2 receptors...
P2 receptors in dendritic...
P2 receptors in lymphocytes
P2 receptors in...
P2 receptors in platelets
P2 receptors in erythrocytes
P2 receptors on bone...
Conclusions
References

P2X receptors are ATP-gated ion channels---originally cloned and characterized in excitable cells44,45 and then shown to be nearly ubiquitous24,46,47---that mediate fast permeability changes to monovalent and divalent cations (Na+, K+, and Ca++). One of the members of this subfamily, P2X7, has sparked vivid interest for its peculiar ability to undergo a progressive increase in size that leads to the generation of a nonselective membrane pore22,48-50 (Figures 1 and 2). All P2X receptors are likely to be multimeric structures of which 7 basic subunits have been cloned. The subunit composition of the native receptors has been resolved only in one case: rat dorsal ganglia that express a P2X2/P2X3 heteromer.51 It is not known how P2X receptors assemble for most cell types. Subunit stoichiometry is likewise unknown but for P2X1 and P2X3, which have been shown to assemble as trimers or hexamers.52 Whether other P2X receptors also assemble according to the same stoichiometry is not known. P2X receptors range from 379 to 595 amino acids and are thought to have 2 transmembrane hydrophobic domains separated by a bulky extracellular region harbouring 10 cysteines and 2 to 6 N-linked glycosylation sites.2,30,44,45 The aminotermini and carboxytermini are both on the cytoplasmic side of the plasma membrane. This tertiary structure and membrane topology is reminiscent of that of other ion channels such as the epithelial amiloride-sensitive Na+ channel (ENaC), the degenerins cloned from Caenorhabditis elegans, and the inward rectifying K+ channel (Kir).30 Signal transduction occurs via fast Na+ and Ca++ influx and K+ efflux, leading to depolarization of the plasma membrane and an increase in the concentration of cytosolic Ca++ ([Ca++]i). It is likely that the drastic upset in intracellular ion homeostasis caused by P2X receptor opening activates several additional intracellular messengers and enzyme pathways, but few studies are available on this novel and exciting field of P2X receptor biochemistry. Electrophysiologic investigation of recombinant P2X receptor subunits transfected into mammalian recipient cells has allowed identification of fast desensitizing and slowly desensitizing (or nondesensitizing) P2X receptors.53


View larger version (25K):
[in this window]
[in a new window]
 
Figure 2. Permeability transition of P2X7 receptor. A transient stimulation with ATP causes the opening of the P2X7 channel and the concomitant Ca++ and Na+ influx and K+ efflux. However, upon sustained stimulation with ATP, the P2X7 receptor undergoes a transition that generates a reversible membrane pore permeable to several low-molecular-weight hydrophylic solutes (Fura-2/FA, Fura-2 free acid; LY, lucifer yellow; EB, ethidium bromide) and to nucleotides.

Although still on a limited basis, a few anti-P2X antibodies were made available over the last 2 years by single laboratories or commercial sources. Polyclonal antibodies against P2X1, P2X4, and P2X7 can be obtained from at least 2 companies; in a few laboratories sera against all the members of the subfamily have been raised.53,46,49,54 One monoclonal antibody selective for the human P2X7 receptor has been produced and characterized by Buell and colleagues.55 Interestingly, this monoclonal antibody, which recognizes an as yet to be identified epitope on the extracellular domain, inhibits activation of human macrophages by 3'-O-(4-benzoyl)benzoyl-ATP (BzATP), a P2X7 agonist.55

The unique naturally occurring agonist of P2X receptors is ATP, albeit diadenosine polyphosphates, such as P,1P4-diadenosine tetraphosphate (Ap4A) and P,1P6-diadenosine hexaphosphate (Ap6A), are active at P2X1 2, and UTP has been reported to be an agonist at P2X3 as well as P2X1.56,57 There is an ongoing debate, initiated by the pioneeristic experiments of Cockcroft and Gomperts in mast cells,58,59 on whether P2X receptors recognize the bianionic (ATP2-) or tetra-anionic (ATP4-) form of the nucleotide. In physiologic solutions, the free acid ATP4- is complexed by Mg++, Ca++, or H+ to yield various mixtures of MgATP2-, CaATP2-, and HATP3-, whereas a small amount (1%-10%, depending on the divalent cation concentration and the pH) is present as the fully dissociated tetra-anion. Removal of Mg++ and Ca++ and alkalinization of the medium increases the apparent affinity of ATP and BzATP for the native P2Z receptor of mast cells and other cell types58-61 and for the recombinant P2X7 receptor,48,62 but addition of Mg++ quickly terminates stimulation. Interpretation of the effects of divalent cation removal is complicated by the concomitant inhibition of ecto-ATPase/ectonucleotidase activity, because these enzymes require the presence of divalent cations. Slowing of hydrolytic activity prolongs the half-life of the nucleotide, thus increasing its apparent potency. This may explain the finding that the potency of stable ATP analogues, such as alpha , beta -methylene ATP (alpha , beta  MeATP), is unaffected by Ca++ and Mg++ removal.63 This ATP analogue is used to pharmacologically discriminate P2X receptor subtypes: P2X1 and P2X3 are sensitive to low (0.5-5 µM) concentrations, and P2X2 and P2X4-7 are activated by high (>100 µM) doses.2 An often neglected finding is the high potency of BzATP at all P2X---not just P2X7---receptors and its agonist activity at P2Y receptors, a feature that makes this ATP analogue one of the most useful tools for the study of native and recombinant P2X receptors.53

Better antagonists, with better-characterized activity, are available at P2X than at P2Y receptors. PPADS is a noncompetitive inhibitor of most P2X receptors53 and, depending on the experimental conditions, may act irreversibly. Oxidized ATP (oATP) was introduced 7 years ago as a selective P2Z (P2X7) inhibitor,64 but it is likely to show the same P2X antagonist selectivity of PPADS, although no detailed investigation has been carried out. At the effective concentrations (100-300 µM), oATP shows little or no inhibitory activity at P2Y receptors and at ectonucleotidases.64 Action of oATP on ectokinases has not been tested in depth; thus it cannot be excluded that some effects of this compound may be due to inhibition of ectophosphorylation.65 PPADS and oATP likely share the same mechanism of action. Both compounds have aldehyde groups (1 PPADS, 2 oATPs) that can react with unprotonated lysines to form Schiff's bases. It is assumed that they preferentially modify lysine residues in the vicinity of the ATP binding site, but this assumption is yet to be proved. Although PPADS has been used as a P2 blocker for some time, it was only after the introduction of oATP that attention has been paid to the time-dependent and irreversible inhibitory effect of this P5P derivative. Time-dependent and irreversible block is extensively documented for oATP at the P2X7 receptor: A 1- to 2-hour preincubation with this inhibitor, even if followed by extensive rinsing, makes all cells so far investigated fully refractory to ATP stimulation via the P2X7 receptor.64,66-69 Refractoriness lasts several hours, until new receptors are inserted into the plasma membrane.

More recently, Wiley and colleagues have introduced another powerful blocker of P2X7, compound 1-[N,0-bis(5-isoquinolinesulphonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazine (KN-62).70 This molecule was originally used as an inhibitor of the calcium calmodulin-dependent kinase71 and made its first appearance in the purinergic field in a study by Blanchard et al72 aimed at investigating the role of the P2Z receptor in cell-mediated cytotoxicity. KN-62 acts as a competitive inhibitor at nanomolar concentrations and shows a striking species specificity: It is active only at the human and not at the rat or mouse P2X7 receptor.73 KN-62 is a very useful tool for short-term studies, but modification of long-term responses should be interpreted with caution because of concomitant inhibition of calcium calmodulin kinase. Surprenant and colleagues74 have recently shown that Coomassie Brilliant Blue G selectively blocks rat P2X7 with nanomolar affinity.


    P2 receptors in monocyte/macrophages
Top
Abstract
Introduction
P2 receptors: what are...
P2Y receptors
P2X receptors
P2 receptors in...
P2Y and P2X subtype...
Role of P2 receptors...
P2 receptors in dendritic...
P2 receptors in lymphocytes
P2 receptors in...
P2 receptors in platelets
P2 receptors in erythrocytes
P2 receptors on bone...
Conclusions
References

Early studies by Steinberg and Silverstein showed that the J774 mouse macrophage cell line expressed a plasma membrane receptor selectively activated by ATP and a few analogues.60,75 Stimulation of this receptor triggered the same reversible increase in plasma membrane permeability to low-molecular-mass solutes originally described by Cockcroft and Gomperts in rat mast cells.58,59 An intriguing finding of these studies was that stimulation of the ATP-permeabilizing receptor eventually led to cell death.75 This incidental observation stirred interest in the possible physiologic meaning of ATP-dependent cytotoxicity and fostered subsequent studies on the role of P2 receptors in the immune system. At about the same time, Greenberg et al demonstrated that J774 macrophages also expressed P2Y-like receptors coupled to Ca++ mobilization via a mechanism other than the ATP-permeabilizing receptor.76 This was made possible by the selection by Steinberg and colleagues75 of ATP-resistant J774 macrophage clones later shown to lack the P2X7 receptor.77,78

According to the nomenclature proposed by Gordon,4 the macrophage-permeabilizing receptor was named P2Z, analogously to the mast cell and lymphocyte ATP receptor. The receptor responsible for ATP-dependent permeabilization has been referred to as P2Z until very recently and, even after the cloning of P2X7 and the demonstration that its transfection confers susceptibility to ATP-dependent permeabilization, some investigators prefer the P2Z nomenclature to indicate the native ATP-permeabilizing receptor, because it is not clear whether P2X7 is the only constitutive subunit or, rather, the native P2Z receptor is formed by the assembly of P2X7 in association with other P2X subtypes. However, because P2X7 reproduces all known effects of the native P2Z and cells resisting ATP-mediated permeabilization lack P2X7, we will assume heretofore that the macrophage P2Z and P2X7 receptors are the same molecule. As seen below, the picture is more complex in lymphocytes and other cells that do not undergo the typical ATP-dependent permeabilization, although they may express P2X7.


    P2Y and P2X subtype expression by macrophages
Top
Abstract
Introduction
P2 receptors: what are...
P2Y receptors
P2X receptors
P2 receptors in...
P2Y and P2X subtype...
Role of P2 receptors...
P2 receptors in dendritic...
P2 receptors in lymphocytes
P2 receptors in...
P2 receptors in platelets
P2 receptors in erythrocytes
P2 receptors on bone...
Conclusions
References

All murine macrophage lines so far investigated express P2Y receptors coupled to release of Ca++ from intracellular stores and IP3 generation, but the individual subtypes have not been investigated in detail. Functional and molecular expression of P2X7 has been shown in some murine cell lines and in mouse and rat peritoneal macrophages.60,75,79-83 Monocyte-derived human macrophages are susceptible to ATP-mediated permeabilization and express P2X7.66,84,85 Among human macrophage lines, THP-1 and U937 cells express P2Y receptors (P2Y2, P2Y4, and P2Y6),5,86-88 but only the THP-1 monocytic cell line has been reported to express P2X7 to a significant level.88 However, P2X7 receptor expression can differ significantly among cell batches propagated in different laboratories. Monocytes freshly isolated from peripheral blood express P2Y receptors but lack P2X7, whether investigated at the molecular or at the functional level. Although a few studies are available, it is generally agreed that, at the most, 15% to 17% of human monocytes undergo the plasma membrane permeability transitions diagnostic of P2X7 expression when stimulated with ATP.66,84 There appears to be an inverse correlation between P2Y2 and P2X7 expression during monocyte to macrophage maturation: P2Y2 messenger RNA (mRNA) declines while P2X7 mRNA increases.89 Up-regulation of P2X7 and acquisition of P2X7-dependent responses are detectable within 24 hours of seeding human monocytes on plastic dishes. Up-regulation of P2X7 and down-regulation of P2Y2 by the inflammatory mediators interferon-gamma and tumor necrosis factor (TNF)-alpha and by lipopolysaccharide (LPS) have been reported.66,89 In addition, phorbol myristate acetate causes a decrease in P2Y2 mRNA in THP-1 cells.90


    Role of P2 receptors in monocyte/macrophage physiology
Top
Abstract
Introduction
P2 receptors: what are...
P2Y receptors
P2X receptors
P2 receptors in...
P2Y and P2X subtype...
Role of P2 receptors...
P2 receptors in dendritic...
P2 receptors in lymphocytes
P2 receptors in...
P2 receptors in platelets
P2 receptors in erythrocytes
P2 receptors on bone...
Conclusions
References

The first report on the effect of exogenous nucleotides on macrophage function was a paper by Cohn and Parks.91 In this study the authors showed that addition of adenine nucleotides to a mouse macrophage culture resulted in a dramatic increase in pinocytic vesicle formation. After this early study, exogenous nucleotides as a stimulant for macrophages were basically neglected for several years and resurrected only in 1985 by Silverstein and coworkers,92 who reported that extracellular ATP inhibited Fc receptor-mediated phagocytosis and at the same time caused influx of Na+, efflux of K+, and an increase in [Ca++]i. In this study it was also for the first time suggested that macrophages expressed receptors specific for ATP. The possibility that these ATP effects could be due to ATP hydrolysis by plasma membrane ecto-ATPase was ruled out by subsequent papers by Steinberg and Silverstein60,75,76 that reported an in-depth characterization of the macrophage-permeabilizing ATP receptor. It was also soon clear that the ATP receptor coupled to release of Ca++ from intracellular stores (P2Y) and the ATP-permeabilizing (P2Z/P2X7) receptor were 2 separate entities with widely different nucleotide selectivity and affinity and likely involved in different responses.76 In J774 macrophages, the concentration of ATP giving one half of the maximal response (EC50) for Ca++ release from intracellular stores (and which therefore reflects activation of P2Y) is in the range of 50 to 70 µM. In microelectrode impalement experiments, the ATP EC50 for depolarization, presumably reflecting opening of P2X7, was reported to be between 250 and 400 µM,93 but a lower EC50 was reported for P2X7-triggered Ca++ rise in thioglycollate-elicited mouse peritoneal macrophages.94 However, determinations based on the measurement of uptake of fluorescent markers give higher EC50 (1.0-1.5 mM ATP) for the activation of the native mouse P2X7 receptor.76,95 The UTP EC50 for Ca++ release from intracellular stores is between 300 and 500 nM 76 and thus much lower than the ATP EC50.76,94 This suggests that macrophages express P2Y4 or P2Y6 or an endogenous yet to be identified uridine nucleotide-specific receptor. Therefore, it is clear that should ATP release occur in a tissue, macrophage P2Y receptors are likely to be activated more easily and more frequently than P2X7.

An early and, with hindsight, obvious proposal was that macrophages and, in general, inflammatory cells, could use P2Y receptors as very sensitive sensors of cell and tissue damage.76 After all, mammalian cells contain huge amounts (5-10 mM) of ATP in their cytosol; thus, any event that causes even a transient break in the plasma membrane will cause release of ATP into the pericellular environment. Furthermore, it is becoming apparent that frank cell injury or death might not even be necessary for ATP release because shear stress forces and stretching are also powerful stimuli for ATP leakage.8-12 J774 macrophages chemotact in response to micromolar concentrations of ADP but, rather intriguingly, not of UTP.96 Human macrophages in the vicinity of dying K562 cells have been shown in vitro to undergo an increase in [Ca++]i that can be closely mimicked by the addition of cell lysate or of ATP at micromolar doses.97 Precedent treatment with the cell lysate made the macrophages refractory to the subsequent application of ATP, suggesting, although not proving, that a substance contained in the lysate and ATP might converge on the same receptor. Thus it can be hypothesized that ATP and other intracellular nucleotides function as early alarm signals that alert macrophages of even minor cell and tissue damage (a response could be elicited with as little as 100 nM ATP) (Figure 3).


View larger version (39K):
[in this window]
[in a new window]
 
Figure 3. Fate of released ATP: possible role in leukocyte chemotaxis. (A) The intracellular ATP concentration is in the 5 to 10 mM range; thus, an ATP gradient capable of driving leukocyte chemotaxis by acting at P2Y receptors is likely to occur at sites of cell or tissue damage. (B) ATP released into the pericellular milieu can either ligate P2Y or P2X receptors or be hydrolyzed by plasma membrane ecto-ATPases or ecto-ATP diphosphohydrolase (CD39). Hydrolysis of AMP by 5'-nucleotidase generates adenosine that activates P1 purinergic receptors.

The [Ca++]i rise could also be exploited by the macrophages for the potentiation of antimicrobial defense mechanisms. Nucleotides by themselves are unable to activate the macrophage NADPH oxidase but enhance superoxide generation stimulated by phagocytosable particles.98 It is conceivable that P2 receptors could also be used as an amplification system to spread the alarm by generating additional inflammatory mediators. In murine and human macrophages, extracellular ATP triggers release of TNF-alpha and interleukin (IL)-1beta . P2 receptors involved in TNF-alpha release have not been identified and there is accordingly little insight into the molecular mechanism involved. An early report in Raw 264.7 murine macrophages99 suggests that ATP might act by enhancing the level of TNF-alpha mRNA, and this would not require priming by other proinflammatory factors, but a much more detailed investigation is clearly needed.

Participation of P2 receptors in IL-1beta secretion is more firmly established and dissected mechanistically. It has been known for a while that LPS-dependent release of the proinflammatory cytokine IL-1beta from macrophages and microglial cells, in contrast to peripheral blood monocytes, is a slow and inefficient process that leads to extracellular accumulation of minute amounts of this cytokine and mainly of the high-molecular-weight (31-34 kd), uncleaved, biologically inactive, procytokine form.100,101 This finding has led many investigators to postulate that a second stimulus is needed to trigger processing and secretion of the cytokine in its low-molecular-weight (17 kd) biologically active form, but the identity of this second stimulus has remained elusive. In 1991 Hogquist and colleagues observed that extracellular ATP triggered IL-1beta processing and release,102 and in 1992 Gabel and coworkers reported that mature IL-1beta formation could be induced by the K+ ionophore nigericin.101 What is in common between nigericin and ATP? Perregaux and coworkers101 reasoned that both nigericin and ATP decrease intracellular K+ levels60 and that perhaps this ionic perturbation was needed to activate the enzyme that cleaves pro-IL-1beta into mature IL-1beta , ie, IL-1beta -converting enzyme (ICE), also known as caspase-1.103 Later studies fulfilled this prediction because ATP was shown to trigger IL-1beta release via a nonlytic mechanism in many different mononuclear phagocytic cells, and release was inhibited by procedures that prevented K+ efflux 85,104-106 (Figure 4). In support of a key role for K+ in ICE activation, Cheneval et al107 have shown that a reduction in the K+ concentration leads to proteolytic cleavage of isolated recombinant ICE. Interestingly, although proteolytic activation of the isolated enzyme could be induced by a reduction in the concentration of other cations besides K+, autoprocessing of cytoplasmic ICE showed an absolute requirement for K+ depletion.107 That ATP acts via ICE is also demonstrated by the ability of a specific ICE inhibitor, the tetrapeptide YVAD (Tyr-Val-Ala-Asp), to block ATP-dependent IL-1beta maturation.106,108 Furthermore, macrophages isolated from mice deficient in ICE were unable to process pro-IL-1beta upon challenge with LPS plus ATP.109 Finally, involvement of P2X7 in ATP-mediated ICE activation is supported by (a) agonist and antagonist profile of cytokine release,85 (b) blockade by a specific anti-P2X7 monoclonal antibody,55 and (c) detection of ICE proteolytic fragments (p20 and p10) in ATP-stimulated microglial cells.106,110 There are no clues as to how a decrease in K+ concentration may activate ICE autoprocessing; nevertheless, K+ provides a straightforward link between P2X7 and ICE because opening of the P2X7 channel/pore provides a very fast pathway for K+ efflux.60,104 It would be interesting to test whether the same K+-based mechanism of activation also applies to other caspases and how this may be involved in apoptosis.111


View larger version (38K):
[in this window]
[in a new window]
 
Figure 4. Model for P2X7-mediated ICE/caspase-1 activation and IL-1beta maturation. Stimulation with LPS triggers IL-1beta gene transcription and pro-IL-1beta accumulation. Opening of the P2X7 pore by extracellular ATP causes a large K+ efflux that triggers proteolytic activation of ICE and cleavage of pro-IL-1beta . Mature IL-1beta is then secreted through an unknown pathway.

In human monocytes, ATP is a powerful stimulus not only for caspase-1 activation but also for the externalization of mature caspase-1 subunits.112 The meaning of this novel observation is elusive, but it may point to a possible function of activated caspase-1 either in the extracellular space or on the outer leaflet of the plasma membrane. In addition, ATP might trigger IL-1beta release by alternative mechanisms, eg, by inducing exocytosis of IL-1beta -containing specialized vesicles (late endosomes or lysosomes), as recently suggested by Rubartelli and coworkers.113 It is possible that the LPS signal for IL-1beta release consists, at least in part, in an autocrine/paracrine stimulation mediated by ATP secretion, as suggested by studies in human and mouse macrophages and mouse microglia 9,114

Participation of P2X7 in LPS-dependent activation of immune cells might have very interesting and far-reaching practical applications in the treatment of sepsis caused by gram-negative bacteria. In 1994 Proctor and colleagues115 showed that the ATP analogue, 2-methylthio-ATP (2-MeS-ATP), inhibited endotoxin-stimulated release of toxic mediators such as TNF-alpha and IL-1beta and protected mice from endotoxin-induced death. Interpretation of this early experiment is not straightforward, because 2-MeS-ATP is an agonist at P2Y as well as P2X purinoceptors2,3; however, at P2X7 2-MeS-ATP acts as a partial agonist and thus it is conceivable that it might antagonize P2X7 stimulation by locally secreted ATP and reduce LPS-dependent TNF-alpha and IL-1beta release. Altogether, these observations suggest that P2X7 (and maybe other P2 receptors) take part in some crucial but as yet unknown steps in the complex chain of events leading to septic shock, either as a component of a paracrine/autocrine loop9 or as a binding site for LPS.115,116

Stimulation with extracellular nucleotides also switches on the inducible nitric oxide synthase (iNOS),116-118 a key enzyme for the bactericidal activity of macrophages. Nucleotides per se are ineffective, but coexposure to low doses of ATP (or UTP) and LPS produces a much higher stimulation of iNOS activity compared with LPS alone. In murine Raw 264.7 macrophages a prolonged (18 hours) incubation was needed to elicit nitrite release, suggesting that P2 stimulation acted by increasing iNOS gene expression rather than by increasing enzyme activity. Other data suggest that P2 receptors are involved in NO generation in a rather more complex fashion. Denlinger and coworkers showed that pretreatment with 2-MeS-ATP prevented iNOS expression and NO generation due to the subsequent addition of LPS,117 raising the issue of the possible participation of P2 receptors in LPS-dependent signaling.116,117 In addition, it has been recently shown that NO production due to Mycobacterium tuberculosis infection also occurs in P2X7 knockout mice and it is inhibited by P2 blockers,119 thus pointing to the participation of other P2X and P2Y receptors. There are an increasing number of papers suggesting that P2 receptors (namely P2X7) might have a role in endotoxin- or parasite-mediated macrophage stimulation. Besides the studies carried out in our laboratory showing that incubation of macrophages or microglia with oATP or apyrase inhibited LPS-dependent IL-1beta release,9 other groups have reported that LPS-dependent NO release and nuclear factor (NF)-kappa B and mitogen-associated protein kinase (MAPK) activation are profoundly inhibited by oATP or by PPADS.116 MAPK in Raw 264.7 macrophages can also be stimulated via P2Y, but the putative purinergic receptor involved in LPS-dependent activation does not seem to be a member of the P2Y family because oATP or PPADS, which block LPS-dependent stimulation, do not affect MAPK stimulation by UTP.116 In the light of the report that ATP triggers NF-kappa B activation via P2X7 and that this activation is blocked by oATP,110 it is likely that the P2 receptor that participates in LPS-dependent macrophage activation is P2X7.

A common event observed in many reactions involving mononuclear phagocytes is multinucleation: often during chronic inflammatory reactions macrophages differentiate into epithelioid cells that eventually fuse into large polykarions named multinucleated giant cells (MGCs).120 Furthermore, in the bone, osteoclast precursors normally fuse to generate large elements with increasing bone resorption activity. MGCs are a common finding of widespread infectious diseases such as tuberculosis, but little is known about the molecular mechanism underlying fusion. In 1995, Falzoni et al66 suggested that the P2X7 receptor could be involved in MGC formation. Monocyte-derived human macrophages can be induced to fuse in vitro by incubation with concanavalin A or phytohemagglutinin, provided that contaminating lymphocytes are also present.121 Pretreatment with oATP fully inhibits this process, although other responses such as concanavalin A-dependent [Ca++]i changes, chemotaxis, or expression of plasma membrane molecules thought to take part in cell fusion (eg, CD11a, CD18, and CD54) are unaffected.66 We have extended these studies to J774 macrophages and selected several clones that either express P2X7 to a very high level (P2X7plus) or lack it altogether (P2X7less). P2X7plus cells spontaneously fuse in culture to form MGCs of different size and shape, containing from a few to 20 or more nuclei.77 A monoclonal antibody raised against the P2X7 outer domain prevents fusion of human macrophages in culture.122,123

The participation in ICE activation and IL-1beta release, and in MGC formation establishes an intriguing link between the P2X7 receptor and chronic inflammation. Experiments from Molloy et al124 and Lammas et al125 further strengthen this link. Both groups investigated the effect of extracellular ATP on macrophage cultures infected with Mycobacterium bovis (bacille Calmette-Guérin) and reported that P2X7 activation caused killing of the phagocyte as well as of the intracellular pathogen. The mechanism involved is unknown, but a recent paper suggests that it might require activation of phospholipase D.126 Another possibility is that the known vesiculating activity of ATP91,127,128 affects viability of the intracellular pathogen by increasing phagosome-lysosome fusion, as suggested by some of the electron microscopy images reported by Molloy et al.124 In macrophages, stimulation of a phosphatidylcholine-selective phospholipase D by P2X7 agonists was reported as early as 1992 83 and shown to be independent of pore formation and of the ensuing Ca++ influx.129 The mechanism by which an activated phospholipase D might partake in parasite killing is unknown but might be related to the enhanced rate of vesicle fusion observed in ATP-stimulated phagocytes. Ability of macrophages to eliminate intracellular parasites is enhanced upon activation with interferon-gamma 125; thus it might not be a coincidence that this cytokine and other proinflammatory factors also up-regulate P2X7 expression.66,130 It is also intriguing that to kill the intraphagosomal parasite, ATP concentrations cytotoxic for the macrophage need to be used or, in other words, parasite killing appears to be a consequence of macrophage death, as if intracellular parasite elimination via P2X7 was not a primary function of the receptor but rather an accessory consequence of its primary cytotoxic activity.

That extracellular ATP is a potent cytotoxic factor for macrophages was immediately apparent as soon as a thorough investigation of ATP receptors was started in these cells, and P2X7 was quickly identified as the culprit. Initially in Silverstein's and later in our laboratory, murine macrophage clones were selected that showed an almost absolute refractoriness to ATP-mediated cytotoxicity.60,75,76,95 These cells showed a normal mobilization of Ca++ from intracellular stores in response to ATP, but no permeabilization of the plasma membrane, and accordingly lacked reactivity to anti-P2X7 antibodies.77 Blockade of the P2X7 receptor by oATP or KN-62 abrogated ATP-dependent cytotoxicity. The role of P2 receptors in cytotoxicity is usually tested in the presence of exogenous ATP, but it cannot be excluded that ATP spontaneously released by cell monolayers may provide a chronic cytolytic stimulus by acting as an autocrine/paracrine factor. We have tested this hypothesis in P2X7plus J774 macrophage cultures grown to confluence. These macrophage clones show an unusually high rate of spontaneous cell death that can be significantly reduced by pretreatment with oATP or coincubation with apyrase or hexokinase.131 In contrast to the P2X7plus clones, the P2X7less cells have a low rate of spontaneous death that is not affected by the presence of P2X7 blockers or ATP-hydrolyzing enzymes. The mechanism of ATP-dependent death can be either necrosis or apoptosis, depending on the length of incubation in the presence of the nucleotide and the dose. In our hands, ATP-pulsed J774 macrophages appear to die mostly by colloido-osmotic lysis; on the contrary, monocyte-derived human macrophages, which incidentally are more resistant to ATP-mediated cytotoxicity, are prone to die by apoptosis.124,125 It is possible that the propensity of these cells to die by apoptosis is related to their lower susceptibility to ATP because we have previously observed132 that, to set in motion the complex machinery involved in apoptosis, a certain amount of time is needed that is clearly unavailable in those cells that are so sensitive to ATP as to decease quickly. An in-depth investigation of the apoptotic pathways triggered by ATP in macrophages has not been yet carried out, but we know from work in microglial cells that caspase-1, -3, and -8 are activated with the subsequent cleavage of the caspase substrates PARP (poly [ADP-ribose] polymerase) and lamin B.106,133 In addition, the crucial transcription factors, NF-kappa B and NFAT (nuclear factor of activated T cells), are also stimulated.110,134


    P2 receptors in dendritic cells
Top
Abstract
Introduction
P2 receptors: what are...
P2Y receptors
P2X receptors
P2 receptors in...
P2Y and P2X subtype...
Role of P2 receptors...
P2 receptors in dendritic...
P2 receptors in lymphocytes
P2 receptors in...
P2 receptors in platelets
P2 receptors in erythrocytes
P2 receptors on bone...
Conclusions
References

Dendritic cells are a newcomer in the purinergic field. It has been known for a while that epidermal Langerhans' cells posses a powerful plasma membrane formalin-resistant ecto-ATPase that has been used as a histochemical marker,135 but their physiologic function was never understood. In 1993 Girolomoni and coworkers136 demonstrated that human epidermal Langerhans' cells can be permeabilized by ATP, albeit to a lesser degree than human keratinocytes or J774 macrophages. However, inhibition of ecto-ATPase greatly enhanced sensitivity to ATP, and this led these authors to suggest that one of the possible physiologic functions of this ectoenzyme was protection of Langerhans' cells against the noxious effects of extracellular ATP. Scattered reports have then followed suggesting that phagocytic cells of the thymus reticulum express a P2X7-like ATP-permeabilizing receptor,137 but only during the last few years has a systematic study of these receptors been carried out in human and mouse dendritic cells.138-143

Human dendritic cells were found to express mRNA for P2X1, P2X4, P2X5, and P2X7 as well as for P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11 receptors.140 Immunohistochemistry with an anti-P2X7 monoclonal antibody performed in human tonsils shows that a cell population of the marginal zone identified as dendritic cells heavily expresses P2X7.55 Scanty pharmacologic data suggest that at least P2Y1, P2Y2, and P2Y4 are functional and mediate a Ca++ signal in these cells.139 P2X7 functions have been investigated in detail in human and mouse dendritic cells, and available evidence suggests that this receptor mediates cytokine release and might also particpate in antigen presentation.141-142 During their investigation of P2Y receptors in human dendritic cells, Liu et al139 observed that dendritic cells redirect their dendrites toward a nearby patch pipette leaking ATP, an incidental finding that might suggest that dendritic cells, like other mononuclear phagocytes, exhibit a P2Y-mediated chemotactic response to ATP. In addition, it has been shown that stimulation with UTP or uridine diphosphate (but surprisingly not with ATP) provided a potent stimulus for the cytokine gene transcription and secretion.144 Given the high expression of P2X7, it is not surprising that dendritic cells are exceedingly sensitive to the cytotoxic activity of ATP and readily die by apoptosis.141,145 Whether this may have relevance in the overall process of modulation of the immune response is presently unknown.


    P2 receptors in lymphocytes
Top
Abstract
Introduction
P2 receptors: what are...
P2Y receptors
P2X receptors
P2 receptors in...
P2Y and P2X subtype...
Role of P2 receptors...
P2 receptors in dendritic...
P2 receptors in lymphocytes
P2 receptors in...
P2 receptors in platelets
P2 receptors in erythrocytes
P2 receptors on bone...
Conclusions
References

Lymphocyte responsivity to nucleotides has been known for many years: In 1978 Gregory and Kern reported that extracellular ATP stimulated proliferation of mouse thymocytes146; Fishman et al in 1980 observed that in human peripheral lymphocytes ATP suppressed proliferation,147 presumably via generation of adenosine. In 1981 Ikehara et al148 in some way reconcilied these contrasting observations by showing that ATP stimulation of DNA synthesis was observed in lymphoid cells from the thymus and inhibition in cells from spleen, lymph nodes, and peripheral blood. These early observations were followed by a few other studies that overall were of little help in building a coherent picture of the responses of lymphoid cells to extracellular nucleotides, and they remained basically anecdotal.149,150 It was not until the end of the 1980s that a systematic approach to the study of purinergic receptor expression and function in lymphocytes was started.151-157

Human B lymphocytes express P2Y receptors, as indicated by the ability of ATP and many other nucleotides (UTP, GTP, CTP, ITP, ADP, adenosine 5'-O-(3'-thiotriphosphate), ATPgamma S) to trigger Ca++ release from intracellular stores.158 Human B lymphocytes also express P2X receptors, although of which particular subtype is still uncertain. Pharmacologic, electrophysiologic, and reverse transcriptase-polymerase chain reaction (RT-PCR) data suggest that the P2X7 receptor is present in these cells and might be up-regulated in chronic leukocytic leukemia cells (quite intriguingly it appears to be also up-regulated in lymphoblastoid cells from patients with Duchenne dystrophy).154,159-161 Rather surprisingly, however, B lymphocytes do not undergo the typical increase in permeability to aqueous solutes up to 900 d, suggesting that a pore of a smaller size, permeable to molecules up to 320 d, is generated by ATP: although ethidium bromide (314 d) is admitted, propidium bromide (414 d) is excluded.159-162 Furthermore, B lymphocytes are also poorly susceptible to ATP-mediated cytotoxicity. Human peripheral T lymphocytes lack P2Y receptors according to functional and pharmacologic studies but express a P2X-like ATP-activated channel.163 Unpublished data from our laboratory show that these cells express at the mRNA level P2X1, P2X4, and P2X7, although a significant variability is observed among samples from different subjects. ATP and BzATP cause in T lymphocytes a large influx of Na+ and Ca++ from the extracellular medium that is fully prevented by pretreatment with oATP. Like in B lymphocytes, ATP treatment of T lymphocytes generates a pore smaller than that seen in macrophages or in HEK293 cells transfected with the recombinant P2X7.48,62 This might be due to the assembly of P2X1 or P2X4 subunits together with P2X7 into the receptor complex, but this is purely speculative.

Expression of P2 receptors in mouse lymphocytes has been more thoroughly investigated. RT-PCR data show that murine thymocytes express the message for P2X1, P2Y1, and P2Y2 receptors and accordingly undergo Ca++ release from intracellular stores and an increase in plasma membrane permeability to external cations when challenged with ATP.164-166 Steroid hormones or cross-linking of T-cell receptor (TCR) by anti-TCR monoclonal antibody causes a transient enhancement of P2Y2 mRNA, suggesting that this could be an early event in response to a variety of activatory stimuli.167 Sensitivity to ATP in thymocytes changes depending on the stage of maturation: CD4+CD8-TCRhigh thymocytes were found to be very sensitive to ATP-mediated lysis166; large double-positive proliferating thymocytes were much less responsive compared with those terminally differentiated.168 As in the case of human lymphocytes, the cut-off of the ATP-gated plasma membrane channel for mouse lymphocytes appears to be slightly over 300 d (ethidium is admitted, propidium is excluded).166 Functional and pharmacologic data support expression of P2X7 by mouse lymphocytes,155,156,166 but there is little molecular evidence to corroborate this claim. At variance with human lymphocytes, mouse thymocytes are readily killed by ATP.155,156 In double-positive (CD4+CD8+) immature thymocyte populations, expression of P2X1 correlated with susceptibility to undergo apoptosis upon dexamethasone treatment,164 and incubation in the presence of apyrase blocked the process, as if dexamethasone induced P2X1 activation via autocrine/paracrine release of ATP. Ability of extracellular ATP to cause apoptosis of mouse cell lines was initially documented in P-815 mastocytoma and YAC lymphoid cells and subsequentely extended to thymocytes.132,169 Among mouse lymphocytes, cytotoxic T-lymphocyte clones, cytotoxic T lymphocytes from peritoneal exudates, and lymphokine-activated killer cells turned out to be fully insensitive to ATP.132,155 Whether this is due to lack of P2 purinergic receptors or to high expression of ecto-ATPase/ectonucleotidases it is not known. The potent cytotoxic activity of extracellular ATP and the remarkable resistance of cytotoxic T lymphocytes and lymphokine-activated killer cells instigated speculations on the possible participation of ATP receptors in target cell killing, as a pathway alternative or parallel to perforin or lymphotoxin.156,157,170 However, it has been very difficult to provide sound experimental support to this hypothesis.171

The role of P2X receptors in the control of lymphocyte proliferation could be more complex than just being effectors of cell death. We have recently examined the effect of transduction of P2X7less human B-lymphoid cells with the P2X7 receptor complementary DNA and have surprisingly found that its expression confers a proliferation advantage in the absence of serum.172 We have not yet dissected the biochemical mechanism underlying the enhanced growth rate of the P2X7 transfectants, but we believe that it involves autocrine stimulation by ATP, because incubation with apyrase or hexokinase or pretreatment with oATP abrogated proliferation of P2X7 transfectants in the absence of serum.172 Whether these observations are relevant for tumors arising from hemopoietic cells is under investigation.

Stimulation with extracellular ATP causes shedding of the cell adhesion molecule L-selectin (CD62L) and the low-affinity receptor for IgE (CD23) from B chronic lymphocytic leukemic cells.173,174 These cells express P2X7, and agonist/antagonist studies suggest that the receptor involved is P2X7.162 CD23 and L-selectin are normally found in high amounts in sera from patients with B chronic lymphocytic leukemia, and this could be due to ATP-dependent shedding via P2X7 stimulation.


    P2 receptors in polymorphonuclear granulocytes
Top
Abstract
Introduction
P2 receptors: what are...
P2Y receptors
P2X receptors
P2 receptors in...
P2Y and P2X subtype...
Role of P2 receptors...
P2 receptors in dendritic...
P2 receptors in lymphocytes
P2 receptors in...
P2 receptors in platelets
P2 receptors in erythrocytes
P2 receptors on bone...
Conclusions
References

Scattered evidence for a role of extracellular nucleotides in granulocyte responses has been present for a while,175,176 but a systematic investigation was only started at the end of the 1980s.177-181 Most studies concentrated on neutrophils, showing that ATP was able to trigger an increase in [Ca++]i, stimulation of phosphoinositide breakdown, superoxide anion generation, and granule exocytosis (both specific and azurophilic).182,183 In human neutrophils, ATP and UTP were reported to be equipotent for both the [Ca++]i increase and superoxide anion formation,178,179 and ATP was also shown to stimulate phospholipase C and diacylglycerol generation as well as protein kinase C activity.183,184 It is of great interest in the light of the proposed proinflammatory role of extracellular ATP that this nucleotide also increases membrane expression of CD11b/CD18 and adhesion to albumin-coated latex beads.185 Because ATP is released by the endothelium and its local concentration is likely to increase during inflammation as a consequence of inactivation of ecto-ATPases by oxygen radicals,186 up-regulation of adhesion molecules by this nucleotide could be of relevance for leukocyte migration across the vessel wall. ATP also enhances the adhesion between neutrophils and pulmonary endothelial cells, a mechanism that might be relevant in syndromes such as adult respiratory distress syndrome and septic shock.187,188 Of course, it cannot be excluded that the ATP effect could be at least in part mediated by its hydrolysis to adenosine,189 but recent data suggest that ecto-ATPase activity has an inhibitory rather than stimulatory effect on granulocyte-endothelium interaction.190 Dubyak and coworkers reported that chronic stimulation with ATPgamma S or UTP could drive differentiation of myelomonocytic progenitor cells (HL-60 and U937).191 Later studies showed that myeloid progenitors express P2Y1 at earlier and P2Y2 at later stages of differentiation.192 The myeloid progenitors HL-60 cells also express P2 Y11.39

P2 subtype expression has not been thoroughly investigated in neutrophils, mainly because of the lack of selective antibodies. RT-PCR data show that human polymorphonuclear granulocytes express P2Y4 and P2Y6 but not P2Y1 or P2Y2 receptors.5 Among P2X receptors, the presence of P2X7 was shown by Northern blotting and immunocytochemistry.49 It has been suggested that human neutrophils might express receptors for diadenosine polyphosphates,193 but evidence for this is preliminary. Besides neutrophils, eosinophils also express P2 receptors coupled to [Ca++]i increases, actin reorganization, and stimulation of the NADPH oxidase.194,195 Interestingly, eosinophils show locomotive activity in response to ATP, ADP, and GTP.194 No data are available as to the P2 subtypes expressed.


    P2 receptors in platelets
Top
Abstract
Introduction
P2 receptors: what are...
P2Y receptors
P2X receptors
P2 receptors in...
P2Y and P2X subtype...
Role of P2 receptors...
P2 receptors in dendritic...
P2 receptors in lymphocytes
P2 receptors in...
P2 receptors in platelets
P2 receptors in erythrocytes
P2 receptors on bone...
Conclusions
References

ADP is one of the best-known activators of platelet aggregation,25,196-198 but the receptors involved have been, at least partially, identified only during the last 5 years. Stimulation with ADP causes release of Ca++ from intracellular stores, Ca++ influx, phospholipase C activation, inhibition of stimulated adenylate cyclase, shape change, activation of fibrinogen receptors, and aggregation.199-201 ATP and ATP analogues are potent inhibitors of these responses. It has also been shown that ADP causes granule release and thromboxane A2 production.202,203 It was initially thought that these effects were mediated by only one receptor named P2T; however, later studies led to the molecular and pharmacologic characterization in platelets of at least 2 of the known members of the P2 family: P2X1 204-207 and P2Y1.208,209 With the availability of more selective platelet P2Y1 and P2X1 agonists and antagonist, it is becoming evident that the view that these are the P2 receptors solely responsible of ADP-mediated platelet activation is an oversimplification. It is clear that it is possible to block ADP-mediated inhibition of stimulated adenylate cyclase activity without decreasing the ADP-dependent [Ca++]i rise. Thus it is postulated that ADP-triggered platelet activation is mediated by 3 receptors: One not yet cloned receptor (P2TAC) is coupled to inhibition of stimulated adenylate cyclase activity; a second (P2Y1) to phospholipase C activation, InsP3 formation, and Ca++ release from intracellular stores; and a third one (P2X1) to fast Ca++ influx across the plasma membrane.210,211 According to this proposal, the P2TAC receptor would coincide with the platelet P2YADP (written in italics to signify that it is not yet cloned) receptor of the nomenclature established by IUPHAR.2,27 Development of selective platelet P2 receptor antagonists has progressed further than in other cell types, and some have already reached clinical applications. Two thienopyridine compounds, ticlopidine and clopidogrel, inhibit ADP-triggered platelet aggregation presumably by selectively blocking P2YADP. The limited structure-relationship analysis so far carried out suggests that 2-alkylthio-substituted analogues of ATP and AMP (eg, 2-MeS-ATP; 2-methylthioadenylyl 5'-(beta ,gamma -methylene)-diphosphonate [2-MeS-beta ,gamma -Me-ATP]; 2-propylthioadenylyl 5'-(beta ,gamma -difluoromethylene)-diphosphonate [ARL 66096]; and 2-propylthioadenylyl 5'-(beta ,gamma -dichloromethylene)-diphosphonate [ARL 67085]) are selective competitive antagonists at P2YADP, and 3'-substituted AMP analogues (eg, adenosine 3'-phosphate 5'-phosphosulphate [A3P5PS]) are selective P2Y1 antagonists.212 The pharmacology of the platelet P2Y1 receptor was clarified when only high-performance liquid chromatography-purified nucleotides were used and care was taken to avoid degradation of triphosphate analogues to the corresponding diphosphates. These precautions are seldom taken in the analysis of nucleotide effects in other cells, and this may lead to a re-evaluation of the agonist activity of ATP in other cell models. It is likely that full platelet activation requires stimulation and cooperative signaling of all 3 receptors, but the initial data from knockout mice suggest a central role for P2Y1, because P2Y1-deficient animals showed increased bleeding time and reduced collagen- and ADP-induced thromboembolism.213 Interestingly, ADP-mediated adenylate cyclase inhibition was not reduced in platelets from the p2y1-/- mice. A P2X1-deficient (P2X1-/-) mouse is also available,214 but no data on platelet function in this animal have been published. A patient was described who was affected by what appears to be a selective deficit in P2YADP receptor expression215 and, on the other hand, expression of P2Y1 (and P2X1) was found to be normal in a patient affected by a severe deficiency of ADP-triggered platelet activation.216 Presence of a functional ATP-activated P2X1 receptor raises intriguing questions on the interplay among different P2 receptors in platelet physiology, because ATP or ATP analogues were never shown to cause platelet activation. It might be that the P2X1 receptor is chronically desensitized in vivo due to continuous leakage of ATP/ADP from blood or endothelial cells, but this issue clearly needs further scrutiny.217 Injury to blood cells or to the vessel wall releases ATP that is quickly dephosphorylated to ADP by ecto-ATPases expressed on the endothelium. Furthermore, platelets themselves are a major source of ATP and ADP that are stored within dense granules to a concentration of about 1 M. Thus, ADP-triggered secretion activates an autocatalytic cycle of autocrine/paracrine stimulation by released nucleotides.218 Release of ATP from platelets can also feed back on the endothelial cells, inducing secretion of other factors involved in hemostasis and inflammation, such as von Willebrand factor.219 The key role of extracellular ATP and P2 receptors in hemostasis has been underscored by the surprising phenotype of cd39/ATP diphosphohydrolase knockout (cd39-/-) mice.220 It was expected that these mice showed a thrombotic diathesis due to enhanced platelet aggregation, because CD39 has been considered an inhibitor of platelet activation. On the contrary, cd39-/-mice displayed prolonged bleeding times and failure to aggregate. These deficits were shown to be due to P2Y1 receptor desensitization dependent on an increased accumulation of extracellular ATP and were largely corrected by apyrase.


    P2 receptors in erythrocytes
Top
Abstract
Introduction
P2 receptors: what are...
P2Y receptors
P2X receptors
P2 receptors in...
P2Y and P2X subtype...
Role of P2 receptors...
P2 receptors in dendritic...
P2 receptors in lymphocytes
P2 receptors in...
P2 receptors in platelets
P2 receptors in erythrocytes
P2 receptors on bone...
Conclusions
References

Effects of extracellular ATP on erythrocytes were initially reported in 1972 by Parker and Snow,221 who showed that this nucleotide caused Na+ influx and K+ efflux paralleled by an increase in water content. As later demonstrated in other cell types, ion fluxes were prevented by Mg2+ or hexokinase plus glucose and potentiated by ethylenediaminetetraacetic acid. All other nucleotides tested were ineffective. An increase in plasma membrane permeability of erythrocytes was also reported by Trams,222 who showed a dramatic accumulation of extracellular adenylates in the presence of extracellular ATP. These authors concluded that ATP caused a permeability change in erythrocyte plasma membrane that allowed for leakage of cytoplasmic ATP ("ATP-induced ATP release"). These data would suggest the expression by erythrocytes of a P2X7-like receptor, but no further characterization of this phenomenon was carried out. Release of ATP under hypoxic conditions has also been reported,223 but the pathway involved was not elucidated. At variance with P2X, erythrocyte P2Y receptors are more thoroughly characterized. Avian red blood cells express a typical P2Y1 receptor coupled to phospholipase beta  activation via a G protein of the Gq family.224,225 Erythrocytes are an ideal "integrator unit" in the blood because they express P2 receptors and at the same time readily release ATP. These properties, on the one hand, make these cells sensitive to ATP released by other blood elements (eg, platelets) and, on the other hand, endow them with the ability to modulate the function of circulating or endothelial cells by secreting large amounts of this nucleotide. It has been proposed that ATP release from erythrocytes could contribute to regulation of local blood flow by acting at P2Y receptors on vascular endothelium.226,227 ATP has a well-known NO releasing activity; thus, under ischemic conditions, when release from erythrocytes is maximal, ATP could be one of the local factors that counteract the decreased blood flow by inducing vasodilatation.


    P2 receptors on bone marrow hemopoietic precursors
Top
Abstract
Introduction
P2 receptors: what are...
P2Y receptors
P2X receptors
P2 receptors in...
P2Y and P2X subtype...
Role of P2 receptors...
P2 receptors in dendritic...
P2 receptors in lymphocytes
P2 receptors in...
P2 receptors in platelets
P2 receptors in erythrocytes
P2 receptors on bone...
Conclusions
References

According to the few available studies, all hemopoietic precursors isolated from mouse bone marrow, as opposed to stromal cells, are highly sensitive to the cytotoxic effect of ATP.228,229 This phenotypic property has made available a very efficient procedure for the isolation of highly purified marrow stromal cells or the deletion of hemopoietic cell precursors. The cytotoxic mechanisms appear to be dependent on the known pore-forming ability of ATP mediated by P2X7 activation and can be significantly enhanced by including in the reaction medium a low-molecular-weight nonpermeant poisonous agent such as potassium thiocyanate.228,229 This procedure might turn out helpful for the local treatment of tumors of hemopoietic origin.


    Conclusions
Top
Abstract
Introduction
P2 receptors: what are...
P2Y receptors
P2X receptors
P2 receptors in...
P2Y and P2X subtype...
Role of P2 receptors...
P2 receptors in dendritic...
P2 receptors in lymphocytes
P2 receptors in...
P2 receptors in platelets
P2 receptors in erythrocytes
P2 receptors on bone...
Conclusions
References

For many years it was thought that receptors for extracellular nucleotides had a physiologic role only in excitable tissues; however, it is now increasingly clear that they are widespread and involved in signal transduction in several other tissues, including blood cells (Table 2). Drugs based on P2YADP antagonism are already in use as antithrombotic agents, and P2Y1 blockers are being developed for this same purpose. Besides thrombosis, another promising field of application of P2 agonist/antagonist is inflammation. Ability of P2 receptors to mediate chemotaxis (via P2Y), or cytotoxic responses and cytokine secretion (via P2X7), opens an entirely new perspective for the development of anti-inflammatory drugs. Chronic inflammatory diseases might be one of the first targets for the clinical application of selective P2X7 antagonists. These compounds might prove beneficial to reduce IL-1beta release and granuloma formation. Finally, high expression of P2X7 by lymphocytic leukemia cells, and its participation in the control of cell death and proliferation, suggests a novel and as yet fully unexplored approach to the treatment of lymphoproliferative disorders.

                              
View this table:
[in this window]
[in a new window]
 
Table 2. P2 receptors expressed by blood cells


    Note added in proof

Two recent papers suggest that circulating human monocytes express a functional P2X7 receptor coupled to IL-1beta and IL-18 release.233,234 In addition, two papers show that exogeneous ATP can be a differentiation factor for human dendritic cells.235,236


    Footnotes

Submitted May 8, 2000; accepted October 5, 2000.

Supported by grants by the Italian Ministry of Scientific Research (Cofin and 60%), the National Research Council of Italy (Target Project on Biotechnology), the Italian Association for Cancer Research, and Telethon of Italy. J.M.S. supported by a fellowship from the European Community (training grant BMH4-98-5146).

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.

Reprints: Francesco Di Virgilio, Department of Experimental and Diagnostic Medicine, Section of General Pathology, University of Ferrara, Via Borsari, 46, I-44100 Ferrara, Italy; e-mail: fdv{at}dns.unife.it.


    References
Top
Abstract
Introduction
P2 receptors: what are...
P2Y receptors
P2X receptors
P2 receptors in...
P2Y and P2X subtype...
Role of P2 receptors...
P2 receptors in dendritic...
P2 receptors in lymphocytes
P2 receptors in...
P2 receptors in platelets
P2 receptors in erythrocytes
P2 receptors on bone...
Conclusions
References

1. Burnstock G. A basis for distinguishing two types of purinergic receptors. In: Straub RW,Bolis L, eds. Cell Membrane Receptors for Drugs and Hormones: A Multidisciplinary Approach. New York, NY: Raven Press; 1978:107-119.

2. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev. 1998;50:413-492[Abstract/Free Full Text].

3. Abbracchio MP, Burnstock G. Purinoceptors: are there families of P2X and P2Y purinoceptors? Pharmacol Ther. 1994;64:445-475[CrossRef][Medline] [Order article via Infotrieve].

4. Gordon JL. Extracellular ATP: effects, sources and fate. Biochem J. 1986;233:309-319[Medline] [Order article via Infotrieve].

5. Jin J, Dasari VR, Sistare FD, Kunapuli SP. Distribution of P2Y receptor subtypes on hematopoietic cells. Br J Pharmacol. 1998;123:789-794[CrossRef][Medline] [Order article via Infotrieve].

6. Burnstock G. The past, present and future of purine nucleotides as signalling molecules. Neuropharmacology. 1997;36:1127-1139[CrossRef][Medline] [Order article via Infotrieve].

7. Filippini A, Taffs RE, Sitkovsky MV. Extracellular ATP in T-lymphocyte activation: possible role in effector functions. Proc Natl Acad Sci U S A. 1990;87:8267-8271[Abstract/Free Full Text].

8. Jorgensen NR, Geist ST, Civitelli R, Steinberg TH. ATP and gap junction-dependent intercellular calcium signalling in osteoblastic cells. J Cell Biol. 1997;139:497-506[Abstract/Free Full Text].

9. Ferrari D, Chiozzi P, Falzoni S, Hanau S, Di Virgilio F. Purinergic modulation of interleukin-1beta release from microglial cells stimulated with bacterial endotoxin. J Exp Med. 1997;185:579-582[Abstract/Free Full Text].

10. Mitchell CH, Carrè DA, McGlinn AM, Stone RA, Civan MM. A release mechanism for stored ATP in ocular ciliary epithelial cells. Proc Natl Acad Sci U S A. 1998;95:7174-7178[Abstract/Free Full Text].

11. Cotrina ML, Lin JH, Alves-Rodriguez A, et al. Connexins regulate calcium signalling by controlling ATP release. Proc Natl Acad Sci U S A. 1998;95:15735-15740[Abstract/Free Full Text].

12. Jiang Q, Mak D, Devidas S, et al. Cystic fibrosis transmembrane conductance regulator-associated ATP release is controlled by a chloride sensor. J Cell Biol. 1998;143:645-657[Abstract/Free Full Text].

13. Holmsen H, Storm E, Day HJ. Determination of ATP and ADP in blood platelets. Anal Biochem. 1972;46:489-501[CrossRef][Medline] [Order article via Infotrieve].

14. Meyers KM, Holmsen H, Seachord CL. Comparative study of platelet dense granule constituents. Am J Physiol. 1982;243:R454-R461.

15. Kaczmarek E, Koziak K, Sevigny J, et al. Identification and characterization of CD39 vascular ATP diphosphohydrolase. J Biol Chem. 1996;271:33116-33122[Abstract/Free Full Text].

16. Wang TF, Guidotti G. CD39 is an ecto-(Ca2+, Mg2+)-apyrase. J Biol Chem. 1996;271:9898-9901[Abstract/Free Full Text].

17. Zimmermann H, Braun N. Ecto-nucleotidases: molecular structures, catalytic properties and functional roles in the nervous system. Prog Brain Res. 1999;120:371-385[Medline] [Order article via Infotrieve].

18. Beaudoin AR, Grondin G, Gendron FP. Immunolocalization of ATP diphosphohydrolase in pig and mouse brains and sensory organs of the mouse. Prog Brain Res. 1999;120:387-395[Medline] [Order article via Infotrieve].

19. Redegeld FA, Caldwell CC, Sitkovsky MV. Ecto-protein kinases: ecto-domain phosphorylation as a novel target for pharmacological manipulation? Trends Pharmacol Sci. 1999;20:453-459[CrossRef][Medline] [Order article via Infotrieve].

20. Dubyak GR. Signal transduction by P2-purinergic receptors for extracellular ATP. Am J Respir Cell Mol Biol. 1991;4:295-300.

21. Dubyak GR, el-Moatassim C. Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides. Am J Physiol. 1993;265:C577-C606[Abstract/Free Full Text].

22. Di Virgilio F. The P2Z purinoceptor: an intriguing role in immunity, inflammation and cell death. Immunol Today. 1995;16:524-528[CrossRef][Medline] [Order article via Infotrieve].

23. Fredholm BB. Purines and neutrophil leukocytes. Gen Pharmacol. 1997;28:345-350[Medline] [Order article via Infotrieve].

24. Di Virgilio F, Chiozzi P, Falzoni S, et al. Cytolytic P2X purinoceptors. Cell Death Differ. 1998;5:191-199[CrossRef][Medline] [Order article via Infotrieve].

25. Kunapuli SP, Daniel JL. P2 receptor subtypes in the cardiovascular system. Biochem J. 1998;336:513-523.

26. Hourani S, Hall DA. P2T purinoceptors: ADP receptors on platelets. Ciba Found Symp. 1996;198:52-69.

27. IUPHAR Compendium on Receptor Characterization and Classification. International Union of Pharmacology. London: IUPHAR Media; 1998.

28. Burnstock G, Kennedy C. Is there a basis for distinguishing two types of P2-purinoceptor? Gen Pharmacol. 1985;16:433-440[Medline] [Order article via Infotrieve].

29. Barnard EA, Burnstock G, Webb TE. G protein-coupled receptors for ATP and other nucleotides: a new receptor family. Trends Pharmacol Sci. 1994;15:67-70[CrossRef][Medline] [Order article via Infotrieve].

30. North RA. Families of ion channels with two hydrophobic segments. Curr Opin Cell Biol. 1996;8:474-483[CrossRef][Medline] [Order article via Infotrieve].

31. Lustig KD, Shiau AK, Brake AJ, Julius D. Expression cloning of an ATP receptor from mouse neuroblastoma cells. Proc Natl Acad Sci U S A. 1993;90:5113-5117[Abstract/Free Full Text].

32. Webb TE, Simon J, Krishek BJ, et al. Cloning and functional expression of a brain G-protein-coupled ATP receptor. FEBS Lett. 1993;324:219-225[CrossRef][Medline] [Order article via Infotrieve].

33. Communi D, Motte S, Boeynaems J-M, Pirotton S. Pharmacological characterization of the human P2Y4 receptor. Eur J Pharmacol. 1996;317:383-389[CrossRef][Medline] [Order article via Infotrieve].

34. Charlton SJ, Brown CA, Weisman GA, Turner JT, Erb L, Boarder ML. Cloned and transfected P2Y4 receptors: characterization of suramin and PPADS-insensitive response to UTP. Br J Pharmacol. 1996;119:1301-1303[Medline] [Order article via Infotrieve].

35. Chang K, Hanaoka K, Kumada M, Takuwa Y. Molecular cloning and functional analysis of a novel P2 nucleotide receptor. J Biol Chem. 1995;270:26152-26158[Abstract/Free Full Text].

36. Communi D, Parmentier M, Boeynaems JM. Cloning, functional expression and tissue distribution of the human P2Y6 receptor. Biochem Biophys Res Commun. 1996;222:303-308[CrossRef][Medline] [Order article via Infotrieve].

37. Henderson DJ, Elliot DG, Smith GM, Webb TE, Dainty IA. Cloning and characterization of a bovine P2Y receptor. Biochem Biophys Res Commun. 1995;212:648-656[CrossRef][Medline] [Order article via Infotrieve].

38. Ayyanathan K, Webb TE, Sandhu AK, Athwal RS, Barnard EA, Kunapuli SP. Cloning and chromosomal localization of the human P2Y1 purinoceptor. Biochem Biophys Res Commun. 1996;218:783-788[CrossRef][Medline] [Order article via Infotrieve].

39. Communi D, Govaerts C, Parmentier M, Boeynaems JM. Cloning of a human purinergic P2Y receptor coupled to phospholipase and adenylyl cyclase. J Biol Chem. 1997;272:31969-31973[Abstract/Free Full Text].

40. Purkiss JR, Boarder MR. Stimulation of phosphatidate synthesis in endothelial cells in response to P2-receptor activation. Evidence for phospholipase C and phospholipase D involvement, phosphatidate and diacylglycerol interconversion and the role of protein kinase C. Biochem J. 1992;287:31-36.

41. Dunn PM, Blakeley AGH. Suramin: a reversible P2-purinoceptor antagonist in the mouse vas deferens. Br J Pharmacol. 1988;93:243-245[Medline] [Order article via Infotrieve].

42. Boyer JL, Romero-Avila T, Schachter JR, Harden TK. Identification of competitive antagonists of the P2Y1 receptor. Mol Pharmacol. 1996;50:1323-1329[Abstract].

43. Kim YC, Gallo-Rodriguez C, Jang SY, et al. Acyclic analogues of deoxyadenosine 3',5'-bisphosphates as P2Y1 receptor antagonists. J Med Chem. 2000;43:746-755[CrossRef][Medline] [Order article via Infotrieve].

44. Brake AJ, Wagenbach MJ, Julius D. New structural motif for ligand-gated ion channels defined by an ionotropic ATP receptor. Nature. 1994;371:519-523[CrossRef][Medline] [Order article via Infotrieve].

45. Valera S, Hussy N, Evans RJ, et al. A new class of ligand-gated ion channels defined by P2X receptor for extracellular ATP. Nature. 1994;371:516-519[CrossRef][Medline] [Order article via Infotrieve].

46. Buell G, Collo G, Rassendren F. P2X receptors: an emerging channel family. Eur J Neurosci. 1996;8:2221-2228[CrossRef][Medline] [Order article via Infotrieve].

47. Soto F, Garcia-Guzman M, Stuhmer W. Cloned ligand-gated channels activated by extracellular ATP (P2X receptors). J Membr Biol. 1997;160:91-100[CrossRef][Medline] [Order article via Infotrieve].

48. Surprenant A, Rassendren F, Kawashima E, North RA, Buell G. The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science. 1996;272:735-738[Abstract].

49. Collo G, Neidhart S, Kawashima E, Kosco-Vilbois M, North RA, Buell G. Tissue distribution of the P2X7 receptor. Neuropharmacology. 1997;36:1277-1283[CrossRef][Medline] [Order article via Infotrieve].

50. Di Virgilio F, Falzoni S, Mutini C, Sanz JM, Chiozzi P. Purinergic P2X7 receptor: a pivotal role in inflammation and immunomodulation. Drug Dev Res. 1998;45:207-213[CrossRef].

51. Lewis C, Neidhart S, Holy C, North RA, Buell G, Surprenant A. Co-expression of P2X2 and P2X3 receptor subunits can account for ATP-gated currents in sensory neurons. Nature. 1995;377:432-435[CrossRef][Medline] [Order article via Infotrieve].

52. Nicke A, Baumert HG, Rettinger J, et al. P2X1 and P2X3 form stable trimers: a novel structural motif of ligand-gated ion channels. EMBO J. 1998;17:3016-3028[CrossRef][Medline] [Order article via Infotrieve].

53. Evans RJ, Surprenant A, North RA. P2X receptors Turner JT, Weisman GA, Fedan. JS, eds. The P2 Nucleotide Receptors. Totowa, NJ: Humana Press; 1998:43-61.

54. Afework M, Burnstock G. Distribution of P2X receptors in the rat adrenal gland. Cell Tissue Res. 1999;298:449-456[CrossRef][Medline] [Order article via Infotrieve].

55. Buell G, Chessell IP, Michel D, et al. Blockade of human P2X7 receptor function with a monoclonal antibody. Blood. 1998;92:3521-3528[Abstract/Free Full Text].

56. Chen C-C, Akopian AN, Sivilotti L, Colquhoun D, Burnstock G, Wood JN. A P2X purinoceptor expressed by a subset of sensory neurons. Nature. 1995;377:428-431[CrossRef][Medline] [Order article via Infotrieve].

57. Hashimoto M, Kokubun S. Contribution of P2-purinoceptors to neurogenic contraction of rat urinary bladder smooth muscle. Br J Pharmacol. 1995;115:636-640[Medline] [Order article via Infotrieve].

58. Cockcroft S, Gomperts BD. ATP induces nucleotide permeability in rat mast cells. Nature. 1979;279:541-542[CrossRef][Medline] [Order article via Infotrieve].

59. Cockcroft S, Gomperts BD. The ATP4- receptor of rat mast cells. Biochem J. 1980;188:789-798[Medline] [Order article via Infotrieve].

60. Steinberg TH, Silverstein SC. Extracellular ATP4- promotes cation fluxes in the J774 mouse macrophage cell line. J Biol Chem. 1987;262:3118-3122[Abstract/Free Full Text].

61. Pizzo P, Zanovello P, Bronte V, Di Virgilio F. Extracellular ATP causes lysis of mouse thymocytes and activates a plasma membrane ion channel. Biochem J. 1991;274:139-144.

62. Rassendren F, Buell GN, Virginio C, Collo G, North RA, Surprenant A. The permeabilizing ATP receptor, P2X7. Cloning and expression of a human cDNA. J Biol Chem. 1997;272:5482-5486[Abstract/Free Full Text].

63. Trezise DJ, Bell NJ, Kennedy I, Humphrey PPA. Effects of divalent cations on the potency of ATP and related agonists in the rat isolated vagus nerve: implications for P2 purinoceptor classification. Br J Pharmacol. 1994;113:463-470[Medline] [Order article via Infotrieve].

64. Murgia M, Hanau S, Pizzo P, Rippa M, Di Virgilio F. Oxidized ATP: an irreversible inhibitor of the macrophage purinergic P2Z receptor. J Biol Chem. 1993;268:8199-8203[Abstract/Free Full Text].

65. Redegeld FA, Smith P, Apasov S, Sitkovsky MV. Phosphorylation of T-lymphocyte plasma membrane-associated proteins by ectoprotein kinases: implications for a possible role for ectophosphorylation in T-cell effector functions. Biochim Biophys Acta. 1997;1328:151-165[Medline] [Order article via Infotrieve].

66. Falzoni S, Munerati M, Ferrari D, Spisani S, Moretti S, Di Virgilio F. The purinergic P2Z receptor of human macrophage cells: characterization and possible physiological role. J Clin Invest. 1995;95:1207-1216.

67. Wiley JS, Chen JR, Snook MB, Jamieson GP. The P2Z- purinoceptor of human lymphocytes: actions of nucleotide agonists and irreversible inhibition by oxidized ATP. Br J Pharmacol. 1994;112:946-950[Medline] [Order article via Infotrieve].

68. Schulze-Lohoff E, Hugo C, Rost S, et al. Extracellular ATP causes apoptosis and necrosis of cultured mesangial cells via P2Z/P2X7 receptors. Am J Physiol. 1998;275:F962-F971[Abstract/Free Full Text].

69. Solini A, Chiozzi P, Morelli A, Fellin R, Di Virgilio F. Human primary fibroblasts in vitro express a purinergic P2X7 receptor coupled to ion fluxes, microvesicle formation and IL-6 release. J Cell Sci. 1999;112:297-305[Abstract].

70. Gargett CE, Wiley JS. The isoquinoline derivative KN-62: a potent antagonist of the P2Z-receptor of human lymphocytes. Br J Pharmacol. 1997;120:1483-1490[CrossRef][Medline] [Order article via Infotrieve].

71. Kato M, Hagiwara M, Nimura Y, Shionoya S, Hidaka H. Purification and characterization of calcium-calmodulin kinase II from human parathyroid glands. J Endocrinol. 1991;131:155-162[Abstract/Free Full Text].

72. Blanchard DK, Wei S, Duan C, Pericle F, Diaz JI, Djeu JY. Role of extracellular adenosine triphosphate in the cytotoxic T lymphocyte-mediated lysis of antigen presenting cells. Blood. 1995;85:3173-3178[Abstract/Free Full Text].

73. Humphreys BD, Virginio C, Surprenant A, Rice J, Dubyak GR. Isoquinolines as antagonists of the P2X7 nucleotide receptor: high selectivity for the human versus rat receptor homologues. Mol Pharmacol. 1998;54:22-32[Abstract/Free Full Text].

74. Jiang LH, Mackenzie AB, North RA, Surprenant A. Brilliant blue G selecticely blocks ATP-gated rat P2X7 receptors. Mol Pharmacol. 2000;58:82-88[Abstract/Free Full Text].

75. Steinberg TH, Newman AS, Swanson JA, Silverstein SC. ATP4- permeabilizes the plasma membrane of mouse macrophages to fluorescent dyes. J Biol Chem. 1987;262:8884-8888[Abstract/Free Full Text].

76. Greenberg S, Di Virgilio F, Steinberg TH, et al. Extracellular nucleotides mediate Ca2+ fluxes in J774 macrophages by two distinct mechanisms. J Biol Chem. 1988;263:10337-10343[Abstract/Free Full Text].

77. Chiozzi P, Sanz JM, Ferrari D, et al. Spontaneous cell fusion in macrophage cultures expressing high levels of the P2Z/P2X7 receptor. J Cell Biol. 1997;138:697-706[Abstract/Free Full Text].

78. Ferrari D, Chiozzi P, Falzoni S, et al. ATP-mediated cytotoxicity in microglial cells. Neuropharmacology. 1997;36:1295-1301[CrossRef][Medline] [Order article via Infotrieve].

79. Di Virgilio F, Meyer BC, Greenberg S, Silverstein SC. Fc receptor-mediated phagocytosis occurs in macrophages at exceedingly low cytosolic Ca2+ levels. J Cell Biol. 1988;106:657-666[Abstract/Free Full Text].

80. Naumov AP, Kaznacheyeva EV, Kiselyov KI, Kuryshev YA, Mamin AG, Mozhayeva GN. ATP-activated inward currents and calcium-permeable channels in rat macrophage plasma membranes. J Physiol. 1995;486:323-337[Abstract/Free Full Text].

81. Lin WW, Lee YT. Pyrimidinoceptor-mediated activation of phospholipase C and phospholipase A2 in RAW 264.7 macrophages. Br J Pharmacol. 1996;119:261-268[Medline] [Order article via Infotrieve].

82. Ichinose M. Modulation of phagocytosis by P2-purinergic receptors in mouse peritoneal macrophages. Jpn J Physiol. 1995;45:707-721[CrossRef][Medline] [Order article via Infotrieve].

83. el-Moatassim C, Dubyak GR. A novel pathway for the activation of phospholipase D by P2Z purinergic receptors in BAC1.2F5 macrophages. J Biol Chem. 1992;267:23664-23673[Abstract/Free Full Text].

84. Hickman SE, El Khoury J, Greenberg S, Schieren I, Silverstein SC. P2Z adenosine triphosphate receptor activity in cultured human monocyte-derived macrophages. Blood. 1994;84:2452-2456[Abstract/Free Full Text].

85. Ferrari D, Chiozzi P, Falzoni S, et al. Extracellular ATP triggers IL-1beta release by activating the purinergic P2Z receptor of human macrophages. J Immunol. 1997;159:1451-1458[Abstract].

86. Cowen DS, Lazarus HM, Shurin SB, Stoll SE, Dubyak GR. Extracellular adenosine triphosphate activates calcium mobilization in human phagocytic leukocytes and neutrophil/monocyte progenitor cells. J Clin Invest. 1989;83:1651-1660.

87. Fredholm BB, Abbracchio MP, Burnstock G, et al. Towards a revised nomenclature for P1 and P2 receptors. Trends Pharmacol Sci. 1997;18:79-82[Medline] [Order article via Infotrieve].

88. Humphreys BD, Dubyak GR. Induction of the P2z/P2X7 nucleotide receptor and associated phospholipase D activity by lipopolysaccharide and IFNgamma in the human THP-1 monocytic cell line. J Immunol. 1996;157:5627-5637[Abstract].

89. Dubyak GR, Clifford EE, Humphreys BD, Kertesy SB, Martin KA. Expression of multiple ATP receptor subtypes during the differentiation and inflammatory activation of myeloid leukocytes. Drug Dev Res. 1996;39:269-278[CrossRef].

90. Martin KA, Kertesy SB, Dubyak GR. Down-regulation of P2U-purinergic nucleotide receptor messenger RNA expression during in vitro differentiation of human myeloid leukocytes by phorbol esters or inflammatory activators. Mol Pharmacol. 1997;51:97-108[Abstract/Free Full Text].

91. Cohn ZA, Parks E. The regulation of pinocytosis in mouse macrophages, III: the induction of vesicle formation by nucleosides and nucleotides. J Exp Med. 1967;125:457-466[Abstract].

92. Sung SS, Young JD, Origlio AM, Heiple JM, Kaback HR, Silverstein SC. Extracellular ATP perturbs transmembrane ion fluxes, elevates cytosolic [Ca2+]i, and inhibits phagocytosis in mouse macrophages. J Biol Chem. 1985;260:13442-13449[Abstract/Free Full Text].

93. Buisman HP, Steinberg TH, Fischbarg J, et al. Extracellular ATP induces a large nonselective conductance in macrophage plasma membranes. Proc Natl Acad Sci U S A. 1988;85:7988-7992[Abstract/Free Full Text].

94. Alonso-Torre SR, Trautmann A. Calcium responses elicited by nucleotides in macrophages. Interaction between two receptor subtypes. J Biol Chem. 1993;268:18640-18647[Abstract/Free Full Text].

95. Murgia M, Pizzo P, Steinberg TH, Di Virgilio F. Characterization of the cytotoxic effect of extracellular ATP in J774 mouse macrophages. Biochem J. 1992;288:897-901.

96. McCloskey MA, Fan Y, Luther S. Chemotaxis of rat mast cells toward adenine nucleotides. J Immunol. 1999;163:970-977[Abstract/Free Full Text].

97. Oshimi Y, Miyazaki S, Oda S. ATP-induced Ca2+ response mediated by P2U and P2Y purinoceptors in human macrophages: signalling from dying cells to macrophages. Immunology. 1999;98:220-227[CrossRef][Medline] [Order article via Infotrieve].

98. Schmid-Antomarchi H, Schmid-Alliana A, Romey G, et al. Extracellular ATP and UTP control the generation of reactive oxygen intermediates in human macrophages through the opening of a charybdotoxin-sensitive Ca2+-dependent K+ channel. J Immunol. 1997;159:6209-6215[Abstract].

99. Tonetti M, Sturla L, Giovine M, Benatti U, De Flora A. Extracellular ATP enhances mRNA levels of nitric oxice synthase and TNFalpha in lipopolysaccharide-treated RAW 264.7 murine macrophages. Biochem Biophys Res Commun. 1995;214:125-130[CrossRef][Medline] [Order article via Infotrieve].

100. Hogquist KA, Unanue ER, Chaplin DD. Release of IL-1 from mononuclear phagocytes. J Immunol. 1991;147:2181-2186[Abstract].

101. Perregaux D, Barberia J, Lanzetti AJ, Geoghegan KF, Carty TJ, Gabel CA. IL-1beta maturation: evidence that mature cytokine formation can be induced specifically by nigericin. J Immunol. 1992;149:1294-1303[Abstract].

102. Hogquist KA, Nett MA, Unanue ER, Chaplin DD. Interleukin 1 is processed and released during apoptosis. Proc Natl Acad Sci U S A. 1991;88:8485-8489[Abstract/Free Full Text].

103. Budihardo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol. 1999;15:269-290[CrossRef][Medline] [Order article via Infotrieve].

104. Perregaux D, Gabel CA. Interleukin-1beta maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J Biol Chem. 1994;269:15195-15203[Abstract/Free Full Text].

105. Ferrari D, Villalba M, Chiozzi P, Falzoni S, Ricciardi-Castagnoli P, Di Virgilio F. Mouse microglial cells express a plasma membrane pore gated by extracellular ATP. J Immunol. 1996;156:1531-1539[Abstract].

106. Sanz JM, Di Virgilio F. Kinetics and mechanism of ATP-dependent IL-1beta release from microglial cells. J Immunol. 2000;164:4893-4898[Abstract/Free Full Text].

107. Cheneval D, Ramage P, Kastelic T, et al. Increased mature interleukin-1beta secretion from THP-1 cells induced by nigericin is a result of activation of p45 IL-1beta -converting enzyme processing. J Biol Chem. 1998;273:17846-17851[Abstract/Free Full Text].

108. Perregaux DG, Gabel CA. Post-translational processing of murine IL-1: evidence that ATP-induced release of IL-1alpha and IL-1beta occurs via a similar mechanism. J Immunol. 1998;160:2469-2477[Abstract/Free Full Text].

109. Li P, Allen H, Banerjee S, et al. Mice deficient in IL-1beta -convering enzyme are defective in production of mature IL-1beta and resistant to endotoxic shock. Cell. 1995;80:401-411[CrossRef][Medline] [Order article via Infotrieve].

110. Ferrari D, Wesselborg S, Bauer MKA, Schulze-Osthoff K. Extracellular ATP activates transcription factor NF-kappa B through the P2Z purinoceptor by selectively targeting NF-kappa B p65. J Cell Biol. 1997;139:1635-1643[Abstract/Free Full Text].

111. Dallaporta B, Marchetti P, de Pablo MA, et al. Plasma membrane potential in thymocyte apoptosis. J Immunol. 1999;162:6534-6542[Abstract/Free Full Text].

112. Laliberte RE, Eggler J, Gabel CA. ATP treatment of human monocytes promotes caspase-1 maturation and externalization. J Biol Chem. 1999;274:36944-36951[Abstract/Free Full Text].

113. Andrei C, Dazzi C, Lotti L, Torrisi MR, Chimini G, Rubartelli A. The secretory route of the leaderless protein interleukin 1beta involved exocytosis of the endolysosome-related vesicles. Mol Biol Cell. 1999;10:1463-1475[Abstract/Free Full Text].

114. Sperlagh B, Hasko G, Nemeth Z, Vizi ES. ATP released by LPS increases nitric oxide production in Raw 264.7 macrophage cell line via P2Z/P2X7 receptors. Neurochem Int. 1998;33:209-215[CrossRef][Medline] [Order article via Infotrieve].

115. Proctor RA, Denlinger LC, Leventhal PS, et al. Protection of mice from endotoxic death by 2-methylthio-ATP. Proc Natl Acad Sci U S A. 1994;91:6017-6020[Abstract/Free Full Text].

116. Hu Y, Fisette PL, Denlinger LC, et al. Purinergic receptor modulation of lipopolysaccharide signalling and inducible nitric-oxide synthase expression in Raw 264.7 macrophages. J Biol Chem. 1998;273:27170-27175[Abstract/Free Full Text].

117. Denlinger LC, Fisette PL, Garis KA, et al. Regulation of inducible nitric oxide synthase expression by macrophage purinoreceptors and calcium. J Biol Chem. 1996;271:337-342[Abstract/Free Full Text].

118. Tonetti M, Sturla L, Bistolfi T, Benatti U, De Flora A. Extracellular ATP potentiates nitric oxide synthase expression induced by lipopolysaccharide in RAW 264.7 murine macrophages. Biochem Biophys Res Commun. 1994;203:430-435[CrossRef][Medline] [Order article via Infotrieve].

119. Sikora A, Liu J, Brosnan C, Buell G, Chessel I, Bloom BR. Cutting edge: purinergic signaling regulates radical-mediated bacterial killing mechanisms in macrophages through a P2X7-independent mechanism. J Immunol. 1999;163:558-561[Abstract/Free Full Text].

120. Fais S, Burgio VL, Capobianchi MR, Gessani S, Pallone F, Belardelli F. The biological relevance of polykarions in the immune response. Immunol Today. 1997;18:522-527[CrossRef][Medline] [Order article via Infotrieve].

121. Takashima T, Ohnishi K, Tsuyuguchi I, Kishimoto S. Differential regulation of formation of multinucleated giant cells from concanavalin A-stimulated human blood monocytes by IFN-gamma and IL-4. J Immunol. 1993;150:3002-3010[Abstract].

122. Di Virgilio F, Falzoni S, Chiozzi P, Sanz JM, Ferrari D, Buell GN. ATP receptors and giant cell formation. J Leukoc Biol. 1999;66:723-726[Abstract].

123. Falzoni S, Chiozzi P, Ferrari D, Buell G, Di Virgilio F. P2X7 receptor and polykarion formation. Mol Biol Cell. 2000;11:3169-3176[Abstract/Free Full Text].

124. Molloy A, Laochumroonvorapong P, Kaplan G. Apoptosis, but not necrosis, of infected monocytes is coupled with killing of intracellular bacillus Calmette-Guerin. J Exp Med. 1994;180:1499-1509[Abstract/Free Full Text].

125. Lammas DA, Stober C, Harvey CJ, Kendrick N, Panchalingam S, Kumararatne DS. ATP-induced killing of mycobacteria by human macrophages is mediated by purinergic P2Z/P2X7 receptors. Immunity. 1997;7:433-444[CrossRef][Medline] [Order article via Infotrieve].

126. Kusner DJ, Adams J. ATP-induced killing of virulent Mycobacterium tuberculosis within human macrophages requires phospholipase D. J Immunol. 2000;164:379-388[Abstract/Free Full Text].

127. Steinberg TH, Buisman HP, Greenberg S, Di Virgilio F, Silverstein SC. Effects of extracellular ATP on mononuclear phagocytes. Ann N Y Acad Sci. 1990;603:120-129[CrossRef][Medline] [Order article via Infotrieve].

128. Coutinho-Silva R, Alves LA, Savino W, Persechini PM. A cation non-selective channel induced by extracellular ATP in macrophages and phagocytic cells of the thymic reticulum. Biochim Biophys Acta. 1996;1278:125-130[Medline] [Order article via Infotrieve].

129. el-Moatassim C, Dubyak GR. Dissociation of the pore-forming and phospholipase D activities stimulated via P2Z purinergic receptors in BAC1.2F5 macrophages. Product inhibition of phospholipase D enzyme activity. J Biol Chem. 1993;268:15571-15581[Abstract/Free Full Text].

130. Humphreys BD, Dubyak GR. Modulation of P2X7 nucleotide receptor expression by pro- and anti-inflammatory stimuli in THP-1 monocytes. J Leukoc Biol. 1998;64:265-273[Abstract].

131. Chiozzi P, Murgia M, Falzoni S, Ferrari D, Di Virgilio F. Role of the purinergic P2Z receptor in spontaneous cell death in J774 macrophage cultures. Biochem Biophys Res Commun. 1996;218:176-181[CrossRef][Medline] [Order article via Infotrieve].

132. Zanovello P, Bronte V, Rosato A, Pizzo P, Di Virgilio F. Responses of mouse lymphocytes to extracellular ATP. II. Extracellular ATP causes cell type-dependent lysis and DNA fragmentation. J Immunol. 1990;145:1545-1550[Abstract].

133. Ferrari D, Los M, Bauer MK, Vandenabeele P, Wesselborg S, Schulze-Osthoff K. P2Z purinoceptor ligation induces activation of caspases with distinct roles in apoptotic and necrotic alterations of cell death. FEBS Lett. 1999;447:71-75[CrossRef][Medline] [Order article via Infotrieve].

134. Ferrari D, Stroh C, Schulze-Osthoff K. P2X7/P2Z purinoceptor-mediated activation of transcription factor NFAT in microglial cells. J Biol Chem. 1999;274:13205-13210[Abstract/Free Full Text].

135. Chaker MB, Tharp MD, Bergstresser PR. Rodent epidermal Langerhans cells demonstrate greater histochemical specificity for ADP than for ATP and AMP. J Invest Dermatol. 1984;82:496-500[CrossRef][Medline] [Order article via Infotrieve].

136. Girolomoni G, Santantonio ML, Pastore S, Bergstresser PR, Giannetti A, Cruz PD Jr. Epidermal Langerhans cells are resistant to the permeabilizing effects of extracellular ATP: in vitro evidence supporting a protective role of membrane ATPase. J Invest Dermatol. 1993;100:282-287[CrossRef][Medline] [Order article via Infotrieve].

137. Coutinho-Silva R, Alves LA, Campos-de-Carvalho AC, Savino W, Persechini PM. Characterization of P2Z purinergic receptors on phagocytic cells of the thymic reticulum in culture. Biochim Biophys Acta. 1996;1280:217-222[Medline] [Order article via Infotrieve].

138. Alves LA, Coutinho-Silva R, Savino W. Extracellular ATP: a further modulator in neuroendocrine control of the thymus. Neuroimmunomodulation. 1999;6:81-89[CrossRef][Medline] [Order article via Infotrieve].

139. Liu Q, Bohlen H, Titzer S, et al. Expression and a role of functionally coupled P2Y receptors in human dendritic cells. FEBS Lett. 1999;445:402-408[CrossRef][Medline] [Order article via Infotrieve].

140. Berchtold S, Ogilvie AL, Bogdan C, et al. Human monocyte derived dendritic cells express functional P2X and P2Y receptors as well as ecto-nucleotidases. FEBS Lett. 1999;458:424-428[CrossRef][Medline] [Order article via Infotrieve].

141. Mutini C, Falzoni S, Ferrari D, et al. Mouse dendritic cells express the P2X7 purinergic receptor: characterization and possible participation in antigen presentation. J Immunol. 1999;163:1958-1965[Abstract/Free Full Text].

142. Ferrari D, La Sala A, Chiozzi P, et al. The P2 purinergic receptors of human dendritic cells: identification and coupling to cytokine release. FASEB J. In press.

143. Nihei OK, de Carvalho AC, Savino W, Alves LA. Pharmacological properties of P2Z/P2X7 receptor characterized in murine dendritic cells: role on the induction of apoptosis. Blood. 2000;96:996-1005[Abstract/Free Full Text].

144. Marriott I, Inscho EW, Bost KL. Extracellular uridine nucleotides initiate cytokine production by murine dendritic cells. Cell Immunol. 1999;195:147-156[CrossRef][Medline] [Order article via Infotrieve].

145. Coutinho-Silva R, Persechini PM, Bisaggio RD, et al. P2Z/P2X7 receptor-dependent apoptosis of dendritic cells. Am J Physiol. 1999;276:C1139-C1147[Abstract/Free Full Text].

146. Gregory SH, Kern M. Adenosine and adenine nucleotides are mitogenic for mouse thymocytes. Biochem Biophys Res Commun. 1978;83:1111-1116[CrossRef][Medline] [Order article via Infotrieve].

147. Fishman RF, Rubin AL, Novogrodsky A, Stenzel KH. Selective suppression of blastogenesis induced by different mitogens: effect of noncyclic adenosine-containing compounds. Cell Immunol. 1980;54:129-139[CrossRef][Medline] [Order article via Infotrieve].

148. Ikehara S, Pahwa RN, Lunzer DG, Good RA, Modak MJ. Adenosine 5'-triphosphate (ATP)-mediated stimulation and suppression of DNA synthesis in lymphoid cells, I: characterization of ATP responsive cells in mouse lymphoid organs. J Immunol. 1981;127:1834-1838[Abstract].

149. Schmidt A, Ortaldo JR, Herberman RB. Inhibition of human natural killer cell reactivity by exogenous adenosine 5'-triphosphate. J Immunol. 1984;132:146-150[Abstract].

150. Lin J, Krishnaraj R, Kemp RG. Exogenous ATP enhances calcium influx in intact thymocytes. J Immunol. 1985;135:3403-3410[Abstract].

151. el-Moatassim C, Dornand J, Mani JC. Extracellular ATP increases cytosolic free calcium in thymocytes and initiates the blastogenesis of the phorbol 12-myristate 13-acetate-treated medullary population. Biochim Biophys Acta. 1987;927:437-444[Medline] [Order article via Infotrieve].

152. el-Moatassim C, Maurice T, Mani JC, Dornand J. The [Ca2+]i increase induced in murine thymocytes by extracellular ATP does not involve ATP hydrolysis and is not related to phosphoinositide metabolism. FEBS Lett. 1989;242:391-396[CrossRef][Medline] [Order article via Infotrieve].

153. el-Moatassim C, Bernad N, Mani JC, Dornand J. Extracellular ATP induces a non-specific permeability of thymocyte plasma membranes. Biochem Cell Biol. 1989;67:495-502[Medline] [Order article via Infotrieve].

154. Wiley JS, Dubyak GR. Extracellular adenosine triphosphate increases cation permeability of chronic lymphocytic leukemic lymphocytes. Blood. 1989;73:1316-1323[Abstract/Free Full Text].

155. Di Virgilio F, Bronte V, Collavo D, Zanovello P. Responses of mouse lymphocytes to extracellular adenosine 5'-triphosphate (ATP). Lymphocytes with cytotoxic activity are resistant to the permeabilizing effect of ATP. J Immunol. 1989;143:1955-1960[Abstract].

156. Filippini A, Taffs RE, Agui T, Sitkovsky MV. Ecto-ATPase activity in cytolytic T lymphocytes. Protection from the cytolytic effects of extracellular ATP. J Biol Chem. 1990;265:334-340[Abstract/Free Full Text].

157. Di Virgilio F, Pizzo P, Zanovello P, Bronte V, Collavo D. Extracellular ATP as a possible mediator of cell-mediated cytotoxicity. Immunol Today. 1990;11:274-277[CrossRef][Medline] [Order article via Infotrieve].

158. Padeh S, Cohen A, Roifman CM. ATP-induced activation of human B lymphocytes via P2-purinoceptors. J Immunol. 1991;146:1626-1632[Abstract].

159. Wiley JS, Chen R, Jamieson GP. The ATP4- receptor-operated channel (P2Z class) of human lymphocytes allows Ba2+ and ethidium+ uptake: inhibition of fluxes by suramin. Arch Biochem Biophys. 1993;305:54-60[CrossRef][Medline] [Order article via Infotrieve].

160. Ferrari D, Munerati M, Melchiorri L, Hanau S, Di Virgilio F, Baricordi OR. Responses to extracellular ATP of lymphoblastoid cell lines from Duchenne muscular dystrophy patients. Am J Physiol. 1994;267:C886-C892[Abstract/Free Full Text].

161. Markwardt F, Lohn M, Bohm T, Klapperstuck M. Purinoceptor-operated cationic channels in human B-lymphocytes. J Physiol. 1997;498:143-151[Abstract/Free Full Text].

162. Wiley JS, Gargett CE, Zhang W, Snook MB, Jamieson GP. Partial agonists and antagonists reveal a second permeability state of human lymphocyte P2Z/P2X7 channel. Am J Physiol. 1998;275:C1224-C1231[Abstract/Free Full Text].

163. Baricordi OR, Ferrari D, Melchiorri L, et al. An ATP-activated channel is involved in mitogenic stimulation of human T lymphocytes. Blood. 1996;87:682-690[Abstract/Free Full Text].

164. Chvatchko Y, Valera S, Aubry JP, Renno T, Buell G, Bonnefoy JY. The involvement of an ATP-gated ion channel, P2X1, in thymocyte apoptosis. Immunity. 1996;5:275-283[CrossRef][Medline] [Order article via Infotrieve].

165. Apasov SG, Koshiba M, Chused TM, Sitkovsky MV. Effects of extracellular ATP and adenosine on different thymocyte subsets. Possible role of ATP-gated channels and G protein-coupled purinergic receptor. J Immunol. 1997;158:5095-5105[Abstract].

166. Chused TM, Apasov S, Sitkovsky M. Murine T lymphocytes modulate activity of an ATP-activated P2Z-type purinoceptor during differentiation. J Immunol. 1996;157:1371-1380[Abstract].

167. Koshiba M, Apasov S, Sverdlov V, et al. Transient up-regulation of P2Y2 nucleotide receptor mRNA expression is an immediate early gene response in activated thymocytes. Proc Natl Acad Sci U S A. 1997;94:831-836[Abstract/Free Full Text].

168. Ross PE, Ehring GR, Cahalan MD. Dynamics of ATP-induced calcium signalling in single mouse thymocytes. J Cell Biol. 1997;138:987-998[Abstract/Free Full Text].

169. Zheng LM, Zychlinsky A, Liu CC, Ojcius DM, Young JD. Extracellular ATP as a trigger for apoptosis or programmed cell death. J Cell Biol. 1991;112:279-288[Abstract/Free Full Text].

170. Steinberg TH, Di Virgilio F. Cell-mediated cytotoxicity: ATP as an effector and the role of target cells. Curr Opin Immunol. 1991;3:71-75[CrossRef][Medline] [Order article via Infotrieve].

171. Zambon A, Bronte V, Di Virgilio F, et al. Role of extracellular ATP in cell-mediated cytotoxicity: a study with ATP-sensitive and ATP-resistant macrophages. Cell Immunol. 1994;156:458-467[CrossRef][Medline] [Order article via Infotrieve].

172. Baricordi OR, Melchiorri L, Adinolfi E, et al. Increased proliferation rate of lymphoid cells transfected with the P2X7 ATP receptor. J Biol Chem. 1999;274:33206-33208[Abstract/Free Full Text].

173. Jamieson GP, Snook MB, Thurlow PJ, Wiley JS. Extracellular ATP causes loss of L-selectin from human lymphocytes via occupancy of P2Z purinoceptors. J Cell Physiol. 1996;166:637-642[CrossRef][Medline] [Order article via Infotrieve].

174. Gu B, Bendall LG, Wiley JS. Adenosine triphosphate-induced shedding of CD23 and L-selectin (CD62L) from lymphocytes is mediated by the same receptor but different metalloproteases. Blood. 1998;92:946-951[Abstract/Free Full Text].

175. Tou JS, Maier C. Phospholipid metabolism and lysosomal enzyme secretion by leukocytes. Effects of dibutyryl cyclic adenosine 3':5'-monophosphate and ATP. Biochim Biophys Acta. 1976;451:353-362[Medline] [Order article via Infotrieve].

176. LeRoy EC, Ager A, Gordon JL. Effects of neutrophil elastase and other proteases on porcine aortic endothelial prostaglandin I2 production, adenine nucleotide release, and responses to vasoactive agents. J Clin Invest. 1984;74:1003-1010.

177. Ward PA, Cunningham TW, McCulloch KK, Phan SH, Powell J, Johnson KJ. Platelet enhancement of O2- responses in stimulated human neutrophils. Identification of platelet factor as adenine nucleotides. Lab Invest. 1988;58:37-47[Medline] [Order article via Infotrieve].

178. Ward PA, Cunningham TW, McCulloch KK, Johnson KJ. Regulatory effects of adenosine and adenine nucleotides on oxygen radical responses of neutrophils. Lab Invest. 1988;58:438-447[Medline] [Order article via Infotrieve].

179. Kuroki M, Minakami S. Extracellular ATP triggers superoxide production in human neutrophils. Biochem Biophys Res Commun. 1989;162:377-380[CrossRef][Medline] [Order article via Infotrieve].

180. Kuroki M, Takeshige K, Minakami S. ATP-induced calcium mobilization in human neutrophils. Biochim Biophys Acta. 1989;1012:103-106[Medline] [Order article via Infotrieve].

181. Dubyak GR, Cowen DS. Activation of inositol phospholipid-specific phospholipase C by P2-purinergic receptors in human phagocytic leukocytes: role of pertussis toxin-sensitive G proteins. Ann N Y Acad Sci. 1990;603:227-245[Medline] [Order article via Infotrieve].

182. Cockcroft S, Stutchfield J. ATP stimulates secretion in human neutrophils and HL60 cells via a pertussis toxin-sensitive guanine nucleotide-binding protein coupled to phospholipase C. FEBS Lett. 1989;245:25-29[CrossRef][Medline] [Order article via Infotrieve].

183. Balazovich KJ, Boxer LA. Extracellular adenosine nucleotides stimulate protein kinase C activity and human neutrophil activation. J Immunol. 1990;144:631-637[Abstract].

184. Cowen DS, Sanders M, Dubyak G. P2-purinergic receptors activate a guanine nucleotide-dependent phospholipase C in membranes from HL-60 cells. Biochim Biophys Acta. 1990;1053:195-203[Medline] [Order article via Infotrieve].

185. Freyer DR, Boxer LA, Axtell RA, Todd RF. Stimulation of human neutrophil adhesive properties by adenine nucleotides. J Immunol. 1988;141:580-586[Abstract].

186. Robson SC, Kaczmarek E, Siegel JB, et al. Loss of ATP diphosphohydrolase activity with endothelial cell activation. J Exp Med. 1997;185:153-163[Abstract/Free Full Text].

187. Dawicki DD, McGowan-Jordan J, Bullard S, Pond S, Round S. Extracellular nucleotides stimulate leukocyte adherence to cultured pulmonary artery endothelial cells. Am J Physiol. 1995;268:L666-L673[Abstract/Free Full Text].

188. Rounds S, Likar LL, Harrington EO, et al. Nucleotide-induced PMN adhesion to cultured epithelial cells: possible role of MUC1 mucin. Am J Physiol. 1999;277:L874-L880[Abstract/Free Full Text].

189. Cronstein BN, Van de Stouwe M, Druska L, Levin RI, Weismann G. Nonsteroidal antiinflammatory agents inhibit stimulated neutrophil adhesion to endothelium: adenosine dependent and independent mechanisms. Inflammation. 1994;18:323-325[CrossRef][Medline] [Order article via Infotrieve].

190. Sud'ina GF, Mirzoeva OK, Galkina SI, Pushkareva MA, Ullrich V. Involvement of ecto-ATPase and extracellular ATP in polymorphonuclear granulocyte-endithelial interactions. FEBS Lett. 1998;423:243-248[CrossRef][Medline] [Order article via Infotrieve].

191. Cowen DS, Berger M, Nuttle L, Dubyak GR. Chronic treatment with P2-purinergic receptor agonists induces phenotypic modulation of the HL-60 and U937 human myelogenous leukemia cell lines. J Leukoc Biol. 1991;50:109-122[Abstract].

192. Clifford EE, Martin KA, Dalal P, Thomas R, Dubyak GR. Stage-specific expression of P2Y receptors, ecto-apyrase and ecto-5'-nucleotidase in myeloid leukocytes. Am J Physiol. 1997;273:C973-C987[Abstract/Free Full Text].

193. Gasmi L, McLennan AG, Edwards SW. Diadenosine polyphosphates induce intracellular Ca2+ mobilization in human neutrophils via a pertussis toxin sensitive G-protein. Immunology. 1997;90:154-159[CrossRef][Medline] [Order article via Infotrieve].

194. Saito H, Ebisawa M, Reason DC, et al. Extracellular ATP stimulates interleukin-dependent cultured mast cell and eosinophils through calcium mobilization. Int Arch Allergy Appl Immunol. 1991;94:68-70[Medline] [Order article via Infotrieve].

195. Dichmann S, Idzko M, Zimpfer U, et al. Adenosine triphosphate-induced oxygen radical production and CD11b up-regulation: Ca2+ mobilization and actin reorganization in human neutrophils. Blood. 2000;95:973-978[Abstract/Free Full Text].

196. Gaarder A, Jonsen A, Laland S, Hellem AJ, Owren P. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature. 1961;192:531-532[CrossRef][Medline] [Order article via Infotrieve].

197. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 1962;194:927-928[Medline] [Order article via Infotrieve].

198. Born GV, Kratzer MAA. Source and concentration of extracellular adenosine triphosphate during haemostasis in rats, rabbits and man. J Physiol. 1984;354:419-429[Abstract/Free Full Text].

199. Gachet C, Hechler B, Leon C, et al. Activation of ADP receptors and platelet function. Thromb Haemost. 1997;78:271-275[Medline] [Order article via Infotrieve].

200. Hourani S, Hall DA. Receptors for ADP of human blood platelets. Trends Pharmacol Sci. 1994;15:103-108[CrossRef][Medline] [Order article via Infotrieve].

201. Mills DC. ADP receptors on platelets. Thromb Haemost. 1996;76:835-856[Medline] [Order article via Infotrieve].

202. Packham MA, Bryant NL, Guccione MA, Kinlough-Rathbone RL, Mustard JF. Effect of the concentration of Ca2+ in the suspending medium on the responses of human and rabbit platelets to aggregating agents. Thromb Haemost. 1989;62:968-976[Medline] [Order article via Infotrieve].

203. Pengo V, Boschello M, Marzari A, Baca M, Schivazappa L, Dalla Volta S. Adenosine diphosphate (ADP)-induced alpha granules release from platelets of native whole blood is reduced by ticlopidine but not by aspirin or dipyridamole. Thromb Haemost. 1986;56:147-150[Medline] [Order article via Infotrieve].

204. MacKenzie AB, Mahaut-Smith MP, Sage SO. Activation of receptor-operated cation channels via P2X1 not P2T purinoceptors in human platelets. J Biol Chem. 1996;271:2879-2881[Abstract/Free Full Text].

205. Vial C, Hechler B, Leon C, Cazenave JP, Gachet C. Presence of P2X1 purinoceptors in human platelets and megakarioblastic cell lines. Thromb Haemost. 1997;78:1500-1504[Medline] [Order article via Infotrieve].

206. Sun B, Li J, Okahara K, Kambayashi J. P2X1 purinoceptor in human platelets. J Biol Chem. 1998;273:11544-11547[Abstract/Free Full Text].

207. Clifford EE, Parker K, Humphreys BD, Kertesy SB, Dubyak GR. The P2X1 receptor, an adenosine triphosphate-gated cation channel, is expressed in human platelets but not in human blood leukocytes. Blood. 1998;91:3172-3181[Abstract/Free Full Text].

208. Leon C, Hechler B, Vial C, Leray C, Cazenave JP, Gachet C. The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets amd megakarioblastic cells. FEBS Lett. 1997;403:26-30[CrossRef][Medline] [Order article via Infotrieve].

209. Savi P, Beauverger P, Labouret C, et al. Role of P2Y1 purinoceptor in ADP-induced platelet activation. FEBS Lett. 1998;422:291-295[CrossRef][Medline] [Order article via Infotrieve].

210. Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP. Molecular basis for ADP-induced platelet activation, I: evidence for three distinct ADP receptors on human platelets. J Biol Chem. 1998;273:2024-2029[Abstract/Free Full Text].

211. Park HS, Hourani SM. Differential effects of adenine nucleotide analogues on shape change and aggregation induced by adenosine 5-diphosphate (ADP) in human platelets. Br J Pharmacol. 1999;127:1359-1366[CrossRef][Medline] [Order article via Infotrieve].

212. Hourani SMO. Pharmacology of the platelet ADP receptors: agonist and antagonist. Haematologica. 2000;85:58-65[Medline] [Order article via Infotrieve].

213. Fabre JE, Nguyen M, Latour A, et al. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med. 1999;5:1199-1202[CrossRef][Medline] [Order article via Infotrieve].

214. Mulryan K, Gitterman DP, Lewis CJ, et al. Reduced vas deferens contraction and male infertility in mice lacking P2X1 receptors. Nature. 2000;403:86-89[CrossRef][Medline] [Order article via Infotrieve].

215. Cattaneo M, Gachet C. ADP receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol. 1999;19:2281-2285[Abstract/Free Full Text].

216. Leon C, Vial C, Gachet C, et al. The P2Y1 receptor is normal in a patient presenting a severe deficiency of ADP-induced platelet aggregation. Thromb Haemost. 1999;81:775-781[Medline] [Order article via Infotrieve].

217. Cusack NJ, Hourani SMO. Platelet P2 receptors: from curiosity to clinical targets. J Auton Nerv Syst. 2000;81:37-43[CrossRef][Medline] [Order article via Infotrieve].

218. Lages B, Weiss HJ. Secreted dense granule adenine nucleotides promote calcium influx and the maintenance of elevated cytosolic calcium levels in stimulated human platelets. Thromb Haemost. 1999;81:286-292[Medline] [Order article via Infotrieve].

219. Vischer UM, Wollheim CB. Purine nucleotides induce regulated secretion of von Willebrand factor: involvement of cytosolic Ca2+ and cyclic adenosine monophosphate-dependent signaling in endothelial exocytosis. Blood. 1998;91:118-127[Abstract/Free Full Text].

220. Enjyoji K, Sevigny J, Lin Y, et al. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med. 1999;5:1010-1017[CrossRef][Medline] [Order article via Infotrieve].

221. Parker JC, Snow RL. Influence of external ATP on permeability and metabolism of dog red blood cells. Am J Physiol. 1972;223:888-893.

222. Trams EG, Kaufman H, Burnstock G. A proposal for the role of ecto-enzymes and adenylates in traumatic shock. J Theor Biol. 1980;87:609-621[CrossRef][Medline] [Order article via Infotrieve].

223. Bergfeld GR, Forrester T. Release of ATP from human erythrocytes in response to a brief period of hypoxia and hypercapnia. Cardiovasc Res. 1992;26:40-47[Abstract/Free Full Text].

224. Berrie CO, Hawkins PT, Stephens LR, Harden TK, Downes CP. Phosphatidylinositol 4,5-bisphosphate hydrolysis in turkey erythrocytes is regulated by P2Y purinoceptors. Mol Pharmacol. 1989;35:526-532[Abstract].

225. Boyer JL, Downes CP, Harden TK. Kinetics of activation of phospholipase C by P2 purinergic agonists and guanine nucleotides. J Biol Chem. 1989;264:884-890[Abstract/Free Full Text].

226. Boeynaems J-M, Pearson JD. P2 purinoceptors on vascular endothelial cells: physiological significance and transduction mechanisms. Trends Pharmacol Sci. 1990;11:34-37[CrossRef][Medline] [Order article via Infotrieve].

227. Boarder MR, Hourani SM. The regulation of vascular function by P2 receptors: multiple sites and multiple receptors. Trends Pharmacol Sci. 1998;19:99-107[CrossRef][Medline] [Order article via Infotrieve].

228. Modderman WE, Vrijheid-Lammers T, Lowik CW, Nijweide PJ. Removal of hematopoietic cells and macrophages from mouse bone marrow cultures: isolation of fibroblast-like stromal cells. Exp Hematol. 1994;22:194-201[Medline] [Order article via Infotrieve].

229. Nijweide PJ, Modderman WE, Hagenaars CE. Extracellular adenosine triphosphate: a shock to hemopoietic cells. Clin Orthop. 1995;313:92-102.

230. Osipchuk Y, Cahalan M. Cell-to-cell calcium signals mediated by ATP receptors in mast cells. Nature. 1992;359:241-244[CrossRef][Medline] [Order article via Infotrieve].

231. Qian YX, McCloskey MA. Activation of mast cell K+ channels through multiple G protein-linked receptors. Proc Natl Acad Sci U S A. 1993;90:7844-7848[Abstract/Free Full Text].

232. Buell G, Michel AD, Lewis C, Collo G, Humphrey PP, Surprenant A. P2X1 receptor activation in HL-60 cells. Blood. 1996;87:2659-2664[Abstract/Free Full Text].

233. Perregaux DG, McNiff P, Laliberte R, Conklyn M, Gabel G. ATP acts as an agonist to promote stimulus-induced secretion of IL-1beta and IL-18 in human blood. J Immunol. 2000;165:4615-4623[Abstract/Free Full Text].

234. Mehta VB, Hart J, Wewers D. ATP stimulated release of IL-1beta and IL-18 requires priming by LPS and is independent of caspase-1 cleavage. J Biol Chem. In press.

235. Schnurr M, Then F, Galambos P, Scholz C, Siegmund B, Endres S, Eigler A. Extracellular ATP and TNF-alpha synergize in the activation of human dendritic cells. J Immunol. 2000;165:4704-4709[Abstract/Free Full Text].

236. La Sala A, Ferrari D, Corinti S, Cavani A, Di Virgilio F, Girolomoni G. Extracellular ATP induces a distorted maturation of dendritic cells and inhibits their capacity to initiate T-helper 1 responses. J Immunol. In press.

© 2001 by The American Society of Hematology.
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
N. Droin, A. Jacquel, J.-B. Hendra, C. Racoeur, C. Truntzer, D. Pecqueur, N. Benikhlef, M. Ciudad, L. Guery, V. Jooste, et al.
Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemia
Blood, January 7, 2010; 115(1): 78 - 88.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Meis, A. Hamacher, D. Hongwiset, C. Marzian, M. Wiese, N. Eckstein, H.-D. Royer, D. Communi, J.-M. Boeynaems, R. Hausmann, et al.
NF546 [4,4'-(Carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene-{alpha},{alpha}'-diphosphonic Acid) Tetrasodium Salt] Is a Non-Nucleotide P2Y11 Agonist and Stimulates Release of Interleukin-8 from Human Monocyte-Derived Dendritic Cells
J. Pharmacol. Exp. Ther., January 1, 2010; 332(1): 238 - 247.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. Rizzo, D. Ferrari, L. Melchiorri, M. Stignani, S. Gulinelli, O. R. Baricordi, and F. Di Virgilio
Extracellular ATP Acting at the P2X7 Receptor Inhibits Secretion of Soluble HLA-G from Human Monocytes
J. Immunol., October 1, 2009; 183(7): 4302 - 4311.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Nicke, Y.-H. Kuan, M. Masin, J. Rettinger, B. Marquez-Klaka, O. Bender, D. C. Gorecki, R. D. Murrell-Lagnado, and F. Soto
A Functional P2X7 Splice Variant with an Alternative Transmembrane Domain 1 Escapes Gene Inactivation in P2X7 Knock-out Mice
J. Biol. Chem., September 18, 2009; 284(38): 25813 - 25822.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
L. Yip, T. Woehrle, R. Corriden, M. Hirsh, Y. Chen, Y. Inoue, V. Ferrari, P. A. Insel, and W. G. Junger
Autocrine regulation of T-cell activation by ATP release and P2X7 receptors
FASEB J, June 1, 2009; 23(6): 1685 - 1693.
[Abstract] [Full Text] [PDF]


Home page
Veterinary PathologyHome page
R. Read, G. Hansen, J. Kramer, R. Finch, L. Li, and P. Vogel
Ectonucleoside Triphosphate Diphosphohydrolase Type 5 (Entpd5)-Deficient Mice Develop Progressive Hepatopathy, Hepatocellular Tumors, and Spermatogenic Arrest
Veterinary Pathology, May 1, 2009; 46(3): 491 - 504.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. Adinolfi, M. G. Callegari, M. Cirillo, P. Pinton, C. Giorgi, D. Cavagna, R. Rizzuto, and F. Di Virgilio
Expression of the P2X7 Receptor Increases the Ca2+ Content of the Endoplasmic Reticulum, Activates NFATc1, and Protects from Apoptosis
J. Biol. Chem., April 10, 2009; 284(15): 10120 - 10128.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
E. Bulanova, V. Budagian, Z. Orinska, F. Koch-Nolte, F. Haag, and S. Bulfone-Paus
ATP induces P2X7 receptor-independent cytokine and chemokine expression through P2X1 and P2X3 receptors in murine mast cells
J. Leukoc. Biol., April 1, 2009; 85(4): 692 - 702.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
F. Scheuplein, N. Schwarz, S. Adriouch, C. Krebs, P. Bannas, B. Rissiek, M. Seman, F. Haag, and F. Koch-Nolte
NAD+ and ATP Released from Injured Cells Induce P2X7-Dependent Shedding of CD62L and Externalization of Phosphatidylserine by Murine T Cells
J. Immunol., March 1, 2009; 182(5): 2898 - 2908.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
A. Mattana, L. Alberti, G. Delogu, P. L. Fiori, and P. Cappuccinelli
In Vitro Activity of Acanthamoeba castellanii on Human Platelets and Erythrocytes
Infect. Immun., February 1, 2009; 77(2): 733 - 738.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
G. R. Dubyak
Both sides now: multiple interactions of ATP with pannexin-1 hemichannels. Focus on "A permeant regulating its permeation pore: inhibition of pannexin 1 channels by ATP"
Am J Physiol Cell Physiol, February 1, 2009; 296(2): C235 - C241.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. K. Ramalingam, C. Hunke, X. Gao, G. Gruber, and P. R. Preiser
ATP/ADP Binding to a Novel Nucleotide Binding Domain of the Reticulocyte-binding Protein Py235 of Plasmodium yoelii
J. Biol. Chem., December 26, 2008; 283(52): 36386 - 36396.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. J. Paredes-Gamero, C. M. M. P. Leon, R. Borojevic, M. E. M. Oshiro, and A. T. Ferreira
Changes in Intracellular Ca2+ Levels Induced by Cytokines and P2 Agonists Differentially Modulate Proliferation or Commitment with Macrophage Differentiation in Murine Hematopoietic Cells
J. Biol. Chem., November 14, 2008; 283(46): 31909 - 31919.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
J. Schachter, A. P. Motta, A. de Souza Zamorano, H. A. da Silva-Souza, M. Z. P. Guimaraes, and P. M. Persechini
ATP-induced P2X7-associated uptake of large molecules involves distinct mechanisms for cations and anions in macrophages
J. Cell Sci., October 1, 2008; 121(19): 3261 - 3270.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
B. Hechler, M. Freund, C. Ravanat, S. Magnenat, J.-P. Cazenave, and C. Gachet
Reduced Atherosclerotic Lesions in P2Y1/Apolipoprotein E Double-Knockout Mice: The Contribution of Non-Hematopoietic-Derived P2Y1 Receptors
Circulation, August 12, 2008; 118(7): 754 - 763.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. Myrtek, T. Muller, V. Geyer, N. Derr, D. Ferrari, G. Zissel, T. Durk, S. Sorichter, W. Luttmann, M. Kuepper, et al.
Activation of Human Alveolar Macrophages via P2 Receptors: Coupling to Intracellular Ca2+ Increases and Cytokine Secretion
J. Immunol., August 1, 2008; 181(3): 2181 - 2188.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. I. A. Roach, R. A. Rebres, I. D. C. Fraser, D. L. DeCamp, K.-M. Lin, P. C. Sternweis, M. I. Simon, and W. E. Seaman
Signaling and Cross-talk by C5a and UDP in Macrophages Selectively Use PLC{beta}3 to Regulate Intracellular Free Calcium
J. Biol. Chem., June 20, 2008; 283(25): 17351 - 17361.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
H. Tozaki-Saitoh, M. Tsuda, H. Miyata, K. Ueda, S. Kohsaka, and K. Inoue
P2Y12 Receptors in Spinal Microglia Are Required for Neuropathic Pain after Peripheral Nerve Injury
J. Neurosci., May 7, 2008; 28(19): 4949 - 4956.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
C. R. Esther Jr, N. E. Alexis, M. L. Clas, E. R. Lazarowski, S. H. Donaldson, C. M. Pedrosa Ribeiro, C. G. Moore, S. D. Davis, and R. C. Boucher
Extracellular purines are biomarkers of neutrophilic airway inflammation
Eur. Respir. J., May 1, 2008; 31(5): 949 - 956.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. Noguchi, K. Ishii, H. Fukutomi, I. Naguro, A. Matsuzawa, K. Takeda, and H. Ichijo
Requirement of Reactive Oxygen Species-dependent Activation of ASK1-p38 MAPK Pathway for Extracellular ATP-induced Apoptosis in Macrophage
J. Biol. Chem., March 21, 2008; 283(12): 7657 - 7665.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Shin, T. Toy, S. Rothenfusser, N. Robson, J. Vorac, M. Dauer, M. Stuplich, S. Endres, J. Cebon, E. Maraskovsky, et al.
P2Y receptor signaling regulates phenotype and IFN-{alpha} secretion of human plasmacytoid dendritic cells
Blood, March 15, 2008; 111(6): 3062 - 3069.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
S. Adriouch, P. Bannas, N. Schwarz, R. Fliegert, A. H. Guse, M. Seman, F. Haag, and F. Koch-Nolte
ADP-ribosylation at R125 gates the P2X7 ion channel by presenting a covalent ligand to its nucleotide binding site
FASEB J, March 1, 2008; 22(3): 861 - 869.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. M. Grbic, E. Degagne, C. Langlois, A.-A. Dupuis, and F.-P. Gendron
Intestinal Inflammation Increases the Expression of the P2Y6 Receptor on Epithelial Cells and the Release of CXC Chemokine Ligand 8 by UDP
J. Immunol., February 15, 2008; 180(4): 2659 - 2668.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
V. L. Kolachala, R. Bajaj, M. Chalasani, and S. V. Sitaraman
Purinergic receptors in gastrointestinal inflammation
Am J Physiol Gastrointest Liver Physiol, February 1, 2008; 294(2): G401 - G410.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
I. A. Kolosova, T. Mirzapoiazova, L. Moreno-Vinasco, S. Sammani, J. G. N. Garcia, and A. D. Verin
Protective effect of purinergic agonist ATP{gamma}S against acute lung injury
Am J Physiol Lung Cell Mol Physiol, February 1, 2008; 294(2): L319 - L324.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Jalkanen and M. Salmi
VAP-1 and CD73, Endothelial Cell Surface Enzymes in Leukocyte Extravasation
Arterioscler Thromb Vasc Biol, January 1, 2008; 28(1): 18 - 26.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D.-J. Jun, J. Kim, S.-Y. Jung, R. Song, J.-H. Noh, Y.-S. Park, S.-H. Ryu, J.-H. Kim, Y.-Y. Kong, J.-M. Chung, et al.
Extracellular ATP Mediates Necrotic Cell Swelling in SN4741 Dopaminergic Neurons through P2X7 Receptors
J. Biol. Chem., December 28, 2007; 282(52): 37350 - 37358.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. R. Vaughan, L. Stokes, L. R. Prince, H. M. Marriott, S. Meis, M. U. Kassack, C. D. Bingle, I. Sabroe, A. Surprenant, and M. K. B. Whyte
Inhibition of Neutrophil Apoptosis by ATP Is Mediated by the P2Y11 Receptor
J. Immunol., December 15, 2007; 179(12): 8544 - 8553.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. Stokes and A. Surprenant
Purinergic P2Y2 Receptors Induce Increased MCP-1/CCL2 Synthesis and Release from Rat Alveolar and Peritoneal Macrophages
J. Immunol., November 1, 2007; 179(9): 6016 - 6023.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
F. Koch-Nolte, J. Reyelt, B. Schossow, N. Schwarz, F. Scheuplein, S. Rothenburg, F. Haag, V. Alzogaray, A. Cauerhff, and F. A. Goldbaum
Single domain antibodies from llama effectively and specifically block T cell ecto-ADP-ribosyltransferase ART2.2 in vivo
FASEB J, November 1, 2007; 21(13): 3490 - 3498.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
O. S. Qureshi, A. Paramasivam, J. C. H. Yu, and R. D. Murrell-Lagnado
Regulation of P2X4 receptors by lysosomal targeting, glycan protection and exocytosis
J. Cell Sci., November 1, 2007; 120(21): 3838 - 3849.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Bendz, S. C. Ruhland, M. J. Pandya, O. Hainzl, S. Riegelsberger, C. Brauchle, M. P. Mayer, J. Buchner, R. D. Issels, and E. Noessner
Human Heat Shock Protein 70 Enhances Tumor Antigen Presentation through Complex Formation and Intracellular Antigen Delivery without Innate Immune Signaling
J. Biol. Chem., October 26, 2007; 282(43): 31688 - 31702.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
S. Kawahara, Y. Hata, M. Miura, T. Kita, A. Sengoku, S. Nakao, Y. Mochizuki, H. Enaida, A. Ueno, A. Hafezi-Moghadam, et al.
Intracellular Events in Retinal Glial Cells Exposed to ICG and BBG
Invest. Ophthalmol. Vis. Sci., October 1, 2007; 48(10): 4426 - 4432.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. Darville, L. Welter-Stahl, C. Cruz, A. A. Sater, C. W. Andrews Jr., and D. M. Ojcius
Effect of the Purinergic Receptor P2X7 on Chlamydia Infection in Cervical Epithelial Cells and Vaginally Infected Mice
J. Immunol., September 15, 2007; 179(6): 3707 - 3714.
[Abstract] [Full Text] [PDF]


Home page
CVIHome page
S.-R. Woo, R. G. Barletta, and C. J. Czuprynski
Extracellular ATP Is Cytotoxic to Mononuclear Phagocytes but Does Not Induce Killing of Intracellular Mycobacterium avium subsp. paratuberculosis
Clin. Vaccine Immunol., September 1, 2007; 14(9): 1078 - 1083.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. Borsellino, M. Kleinewietfeld, D. Di Mitri, A. Sternjak, A. Diamantini, R. Giometto, S. Hopner, D. Centonze, G. Bernardi, M. L. Dell'Acqua, et al.
Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression
Blood, August 15, 2007; 110(4): 1225 - 1232.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. W. Buczynski, D. L. Stephens, R. C. Bowers-Gentry, A. Grkovich, R. A. Deems, and E. A. Dennis
TLR-4 and Sustained Calcium Agonists Synergistically Produce Eicosanoids Independent of Protein Synthesis in RAW264.7 Cells
J. Biol. Chem., August 3, 2007; 282(31): 22834 - 22847.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Adriouch, S. Hubert, S. Pechberty, F. Koch-Nolte, F. Haag, and M. Seman
NAD+ Released during Inflammation Participates in T Cell Homeostasis by Inducing ART2-Mediated Death of Naive T Cells In Vivo
J. Immunol., July 1, 2007; 179(1): 186 - 194.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
M. Baroni, C. Pizzirani, M. Pinotti, D. Ferrari, E. Adinolfi, S. Calzavarini, P. Caruso, F. Bernardi, and F. Di Virgilio
Stimulation of P2 (P2X7) receptors in human dendritic cells induces the release of tissue factor-bearing microparticles
FASEB J, June 1, 2007; 21(8): 1926 - 1933.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
F. Kukulski, F. Ben Yebdri, J. Lefebvre, M. Warny, P. A. Tessier, and J. Sevigny
Extracellular nucleotides mediate LPS-induced neutrophil migration in vitro and in vivo
J. Leukoc. Biol., May 1, 2007; 81(5): 1269 - 1275.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. Pizzirani, D. Ferrari, P. Chiozzi, E. Adinolfi, D. Sandona, E. Savaglio, and F. Di Virgilio
Stimulation of P2 receptors causes release of IL-1{beta}-loaded microvesicles from human dendritic cells
Blood, May 1, 2007; 109(9): 3856 - 3864.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
G. Burnstock
Physiology and Pathophysiology of Purinergic Neurotransmission
Physiol Rev, April 1, 2007; 87(2): 659 - 797.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. Rossi, R. Manfredini, F. Bertolini, D. Ferrari, M. Fogli, R. Zini, S. Salati, V. Salvestrini, S. Gulinelli, E. Adinolfi, et al.
The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration
Blood, January 15, 2007; 109(2): 533 - 542.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. del Rey, V. Renigunta, A. H. Dalpke, J. Leipziger, J. E. Matos, B. Robaye, M. Zuzarte, A. Kavelaars, and P. J. Hanley
Knock-out Mice Reveal the Contributions of P2Y and P2X Receptors to Nucleotide-induced Ca2+ Signaling in Macrophages
J. Biol. Chem., November 17, 2006; 281(46): 35147 - 35155.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
I. Lemaire, S. Falzoni, N. Leduc, B. Zhang, P. Pellegatti, E. Adinolfi, P. Chiozzi, and F. Di Virgilio
Involvement of the Purinergic P2X7 Receptor in the Formation of Multinucleated Giant Cells
J. Immunol., November 15, 2006; 177(10): 7257 - 7265.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
F. O. Martinez, S. Gordon, M. Locati, and A. Mantovani
Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression
J. Immunol., November 15, 2006; 177(10): 7303 - 7311.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
G. Caljon, J. Van Den Abbeele, B. Stijlemans, M. Coosemans, P. De Baetselier, and S. Magez
Tsetse Fly Saliva Accelerates the Onset of Trypanosoma brucei Infection in a Mouse Model Associated with a Reduced Host Inflammatory Response
Infect. Immun., November 1, 2006; 74(11): 6324 - 6330.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
I. Moreschi, S. Bruzzone, R. A. Nicholas, F. Fruscione, L. Sturla, F. Benvenuto, C. Usai, S. Meis, M. U. Kassack, E. Zocchi, et al.
Extracellular NAD+ Is an Agonist of the Human P2Y11 Purinergic Receptor in Human Granulocytes
J. Biol. Chem., October 20, 2006; 281(42): 31419 - 31429.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Tsukimoto, M. Maehata, H. Harada, A. Ikari, K. Takagi, and M. Degawa
P2X7 Receptor-Dependent Cell Death Is Modulated during Murine T Cell Maturation and Mediated by Dual Signaling Pathways.
J. Immunol., September 1, 2006; 177(5): 2842 - 2850.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Carta, S. Tassi, C. Semino, G. Fossati, P. Mascagni, C. A. Dinarello, and A. Rubartelli
Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of microtubules
Blood, September 1, 2006; 108(5): 1618 - 1626.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
O. Levy, M. Coughlin, B. N. Cronstein, R. M. Roy, A. Desai, and M. R. Wessels
The Adenosine System Selectively Inhibits TLR-Mediated TNF-{alpha} Production in the Human Newborn
J. Immunol., August 1, 2006; 177(3): 1956 - 1966.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
G. G. Yegutkin, A. Mikhailov, S. S. Samburski, and S. Jalkanen
The Detection of Micromolar Pericellular ATP Pool on Lymphocyte Surface by Using Lymphoid Ecto-Adenylate Kinase as Intrinsic ATP Sensor
Mol. Biol. Cell, August 1, 2006; 17(8): 3378 - 3385.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
M. Moayeri, K. E. Wickliffe, J. F. Wiggins, and S. H. Leppla
Oxidized ATP Protection against Anthrax Lethal Toxin
Infect. Immun., July 1, 2006; 74(7): 3707 - 3714.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
N. McNamara, M. Gallup, A. Sucher, I. Maltseva, D. McKemy, and C. Basbaum
AsialoGM1 and TLR5 Cooperate in Flagellin-Induced Nucleotide Signaling to Activate Erk1/2
Am. J. Respir. Cell Mol. Biol., June 1, 2006; 34(6): 653 - 660.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
L. C. Denlinger, D. B. Coursin, K. Schell, G. Angelini, D. N. Green, A. G. Guadarrama, J. Halsey, U. Prabhu, K. J. Hogan, and P. J. Bertics
Human P2X7 Pore Function Predicts Allele Linkage Disequilibrium
Clin. Chem., June 1, 2006; 52(6): 995 - 1004.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. Locovei, L. Bao, and G. Dahl
Pannexin 1 in erythrocytes: Function without a gap
PNAS, May 16, 2006; 103(20): 7655 - 7659.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. Ferrari, C. Pizzirani, E. Adinolfi, R. M. Lemoli, A. Curti, M. Idzko, E. Panther, and F. Di Virgilio
The P2X7 Receptor: A Key Player in IL-1 Processing and Release
J. Immunol., April 1, 2006; 176(7): 3877 - 3883.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. A. Khine, L. Del Sorbo, R. Vaschetto, S. Voglis, E. Tullis, A. S. Slutsky, G. P. Downey, and H. Zhang
Human neutrophil peptides induce interleukin-8 production through the P2Y6 signaling pathway
Blood, April 1, 2006; 107(7): 2936 - 2942.
[Abstract] [Full Text] [PDF]


Home page
Plant Physiol.Home page
C. J. Song, I. Steinebrunner, X. Wang, S. C. Stout, and S. J. Roux
Extracellular ATP Induces the Accumulation of Superoxide via NADPH Oxidases in Arabidopsis
Plant Physiology, April 1, 2006; 140(4): 1222 - 1232.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
I. C. Davis, E. R. Lazarowski, J. M. Hickman-Davis, J. A. Fortenberry, F.-P. Chen, X. Zhao, E. Sorscher, L. M. Graves, W. M. Sullender, and S. Matalon
Leflunomide Prevents Alveolar Fluid Clearance Inhibition by Respiratory Syncytial Virus
Am. J. Respir. Crit. Care Med., March 15, 2006; 173(6): 673 - 682.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
G. Burnstock
Pathophysiology and therapeutic potential of purinergic signaling.
Pharmacol. Rev., March 1, 2006; 58(1): 58 - 86.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. Chen and C. F. Brosnan
Exacerbation of Experimental Autoimmune Encephalomyelitis in P2X7R-/- Mice: Evidence for Loss of Apoptotic Activity in Lymphocytes.
J. Immunol., March 1, 2006; 176(5): 3115 - 3126.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. Fellin, T. Pozzan, and G. Carmignoto
Purinergic Receptors Mediate Two Distinct Glutamate Release Pathways in Hippocampal Astrocytes
J. Biol. Chem., February 17, 2006; 281(7): 4274 - 4284.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H. Kawamura, F. Aswad, M. Minagawa, S. Govindarajan, and G. Dennert
P2X7 Receptors Regulate NKT Cells in Autoimmune Hepatitis
J. Immunol., February 15, 2006; 176(4): 2152 - 2160.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. N. Shemon, R. Sluyter, S. L. Fernando, A. L. Clarke, L.-P. Dao-Ung, K. K. Skarratt, B. M. Saunders, K. S. Tan, B. J. Gu, S. J. Fuller, et al.
A Thr357 to Ser Polymorphism in Homozygous and Compound Heterozygous Subjects Causes Absent or Reduced P2X7 Function and Impairs ATP-induced Mycobacterial Killing by Macrophages
J. Biol. Chem., January 27, 2006; 281(4): 2079 - 2086.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. Raffaghello, P. Chiozzi, S. Falzoni, F. Di Virgilio, and V. Pistoia
The P2X7 Receptor Sustains the Growth of Human Neuroblastoma Cells through a Substance P-Dependent Mechanism
Cancer Res., January 15, 2006; 66(2): 907 - 914.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
D. Ferrari, A. la Sala, E. Panther, J. Norgauer, F. Di Virgilio, and M. Idzko
Activation of human eosinophils via P2 receptors: novel findings and future perspectives
J. Leukoc. Biol., January 1, 2006; 79(1): 7 - 15.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Li, D. Liu, H. Z. Ke, R. L. Duncan, and C. H. Turner
The P2X7 Nucleotide Receptor Mediates Skeletal Mechanotransduction
J. Biol. Chem., December 30, 2005; 280(52): 42952 - 42959.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. A. Verhoef, S. B. Kertesy, K. Lundberg, J. M. Kahlenberg, and G. R. Dubyak
Inhibitory Effects of Chloride on the Activation of Caspase-1, IL-1{beta} Secretion, and Cytolysis by the P2X7 Receptor
J. Immunol., December 1, 2005; 175(11): 7623 - 7634.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
C. Geary, H. Akinbi, T. Korfhagen, J.-E. Fabre, R. Boucher, and W. Rice
Increased susceptibility of purinergic receptor-deficient mice to lung infection with Pseudomonas aeruginosa
Am J Physiol Lung Cell Mol Physiol, November 1, 2005; 289(5): L890 - L895.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
F. Aswad, H. Kawamura, and G. Dennert
High Sensitivity of CD4+CD25+ Regulatory T Cells to Extracellular Metabolites Nicotinamide Adenine Dinucleotide and ATP: A Role for P2X7 Receptors
J. Immunol., September 1, 2005; 175(5): 3075 - 3083.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
P. Pellegatti, S. Falzoni, P. Pinton, R. Rizzuto, and F. Di Virgilio
A Novel Recombinant Plasma Membrane-targeted Luciferase Reveals a New Pathway for ATP Secretion
Mol. Biol. Cell, August 1, 2005; 16(8): 3659 - 3665.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
G. Cabrini, S. Falzoni, S. L. Forchap, P. Pellegatti, A. Balboni, P. Agostini, A. Cuneo, G. Castoldi, O. R. Baricordi, and F. Di Virgilio
A His-155 to Tyr Polymorphism Confers Gain-of-Function to the Human P2X7 Receptor of Human Leukemic Lymphocytes
J. Immunol., July 1, 2005; 175(1): 82 - 89.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
E. Adinolfi, M. G. Callegari, D. Ferrari, C. Bolognesi, M. Minelli, M. R. Wieckowski, P. Pinton, R. Rizzuto, and F. Di Virgilio
Basal Activation of the P2X7 ATP Receptor Elevates Mitochondrial Calcium and Potential, Increases Cellular ATP Levels, and Promotes Serum-independent Growth
Mol. Biol. Cell, July 1, 2005; 16(7): 3260 - 3272.
[Abstract] [Full Text] [PDF]


Home page
DevelopmentHome page
V. Resta, E. Novelli, F. Di Virgilio, and L. Galli-Resta
Neuronal death induced by endogenous extracellular ATP in retinal cholinergic neuron density control
Development, June 15, 2005; 132(12): 2873 - 2882.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. D. Granstein, W. Ding, J. Huang, A. Holzer, R. L. Gallo, A. Di Nardo, and J. A. Wagner
Augmentation of Cutaneous Immune Responses by ATP{gamma}S: Purinergic Agonists Define a Novel Class of Immunologic Adjuvants
J. Immunol., June 15, 2005; 174(12): 7725 - 7731.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
Y.-H. Feng, L. Wang, Q. Wang, X. Li, R. Zeng, and G. I. Gorodeski
ATP stimulates GRK-3 phosphorylation and {beta}-arrestin-2-dependent internalization of P2X7 receptor
Am J Physiol Cell Physiol, June 1, 2005; 288(6): C1342 - C1356.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
R. Coutinho-Silva, L. Stahl, K.-K. Cheung, N. E. de Campos, C. de Oliveira Souza, D. M. Ojcius, and G. Burnstock
P2X and P2Y purinergic receptors on human intestinal epithelial carcinoma cells: effects of extracellular nucleotides on apoptosis and cell proliferation
Am J Physiol Gastrointest Liver Physiol, May 1, 2005; 288(5): G1024 - G1035.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
E. Bulanova, V. Budagian, Z. Orinska, M. Hein, F. Petersen, L. Thon, D. Adam, and S. Bulfone-Paus
Extracellular ATP Induces Cytokine Expression and Apoptosis through P2X7 Receptor in Murine Mast Cells
J. Immunol., April 1, 2005; 174(7): 3880 - 3890.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. C. Denlinger, G. Angelini, K. Schell, D. N. Green, A. G. Guadarrama, U. Prabhu, D. B. Coursin, P. J. Bertics, and K. Hogan
Detection of Human P2X7 Nucleotide Receptor Polymorphisms by a Novel Monocyte Pore Assay Predictive of Alterations in Lipopolysaccharide-Induced Cytokine Production
J. Immunol., April 1, 2005; 174(7): 4424 - 4431.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. Krebs, S. Adriouch, F. Braasch, W. Koestner, E. H. Leiter, M. Seman, F. E. Lund, N. Oppenheimer, F. Haag, and F. Koch-Nolte
CD38 Controls ADP-Ribosyltransferase-2-Catalyzed ADP-Ribosylation of T Cell Surface Proteins
J. Immunol., March 15, 2005; 174(6): 3298 - 3305.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Schnurr, T. Toy, A. Shin, M. Wagner, J. Cebon, and E. Maraskovsky
Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and enhances IL-23 expression in human dendritic cells: a novel role for the cAMP pathway
Blood, February 15, 2005; 105(4): 1582 - 1589.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
L. Wang, G. Olivecrona, M. Gotberg, M. L. Olsson, M. S. Winzell, and D. Erlinge
ADP Acting on P2Y13 Receptors Is a Negative Feedback Pathway for ATP Release From Human Red Blood Cells
Circ. Res., February 4, 2005; 96(2): 189 - 196.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
C. D. Douillet, W. P. Robinson III, B. L. Zarzaur, E. R. Lazarowski, R. C. Boucher, and P. B. Rich
Mechanical Ventilation Alters Airway Nucleotides and Purinoceptors in Lung and Extrapulmonary Organs
Am. J. Respir. Cell Mol. Biol., January 1, 2005; 32(1): 52 - 58.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. Feng, A. G. Mery, E. M. Beller, C. Favot, and J. A. Boyce
Adenine Nucleotides Inhibit Cytokine Generation by Human Mast Cells through a Gs-Coupled Receptor
J. Immunol., December 15, 2004; 173(12): 7539 - 7547.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
P. A. Verhoef, S. B. Kertesy, M. Estacion, W. P. Schilling, and G. R. Dubyak
Maitotoxin Induces Biphasic Interleukin-1{beta} Secretion and Membrane Blebbing in Murine Macrophages
Mol. Pharmacol., October 1, 2004; 66(4): 909 - 920.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
F. Marteau, D. Communi, J.-M. Boeynaems, and N. Suarez Gonzalez
Involvement of multiple P2Y receptors and signaling pathways in the action of adenine nucleotides diphosphates on human monocyte-derived dendritic cells
J. Leukoc. Biol., October 1, 2004; 76(4): 796 - 803.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. Ferrari, C. Pizzirani, E. Adinolfi, S. Forchap, B. Sitta, L. Turchet, S. Falzoni, M. Minelli, R. Baricordi, and F. Di Virgilio
The Antibiotic Polymyxin B Modulates P2X7 Receptor Function
J. Immunol., October 1, 2004; 173(7): 4652 - 4660.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
F. S. A. Fortes, I. L. Pecora, P. M. Persechini, S. Hurtado, V. Costa, R. Coutinho-Silva, M. B. M. Braga, F. C. Silva-Filho, R. C. Bisaggio, F. P. de Farias, et al.
Modulation of intercellular communication in macrophages: possible interactions between GAP junctions and P2 receptors
J. Cell Sci., September 15, 2004; 117(20): 4717 - 4726.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. M. Lemoli, D. Ferrari, M. Fogli, L. Rossi, C. Pizzirani, S. Forchap, P. Chiozzi, D. Vaselli, F. Bertolini, T. Foutz, et al.
Extracellular nucleotides are potent stimulators of human hematopoietic stem cells in vitro and in vivo
Blood, September 15, 2004; 104(6): 1662 - 1670.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
G. J. Zwartz, A. Chigaev, D. C. Dwyer, T. D. Foutz, B. S. Edwards, and L. A. Sklar
Real-time Analysis of Very Late Antigen-4 Affinity Modulation by Shear
J. Biol. Chem., September 10, 2004; 279(37): 38277 - 38286.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. F. Hoffman, A. Dodson, A. Wickrema, and S. D. Dib-Hajj
Tetrodotoxin-sensitive Na+ channels and muscarinic and purinergic receptors identified in human erythroid progenitor cells and red blood cell ghosts
PNAS, August 17, 2004; 101(33): 12370 - 12374.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Chigaev, G. J. Zwartz, T. Buranda, B. S. Edwards, E. R. Prossnitz, and L. A. Sklar
Conformational Regulation of {alpha}4{beta}1-Integrin Affinity by Reducing Agents: "INSIDE-OUT" SIGNALING IS INDEPENDENT OF AND ADDITIVE TO REDUCTION-REGULATED INTEGRIN ACTIVATION
J. Biol. Chem., July 30, 2004; 279(31): 32435 - 32443.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. J. Gu, R. Sluyter, K. K. Skarratt, A. N. Shemon, L.-P. Dao-Ung, S. J. Fuller, J. A. Barden, A. L. Clarke, S. Petrou, and J. S. Wiley
An Arg307 to Gln Polymorphism within the ATP-binding Site Causes Loss of Function of the Human P2X7 Receptor
J. Biol. Chem., July 23, 2004; 279(30): 31287 - 31295.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
J. A. Sim, M. T. Young, H.-Y. Sung, R. A. North, and A. Surprenant
Reanalysis of P2X7 Receptor Expression in Rodent Brain
J. Neurosci., July 14, 2004; 24(28): 6307 - 6314.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
C. Andrei, P. Margiocco, A. Poggi, L. V. Lotti, M. R. Torrisi, and A. Rubartelli
From The Cover: Phospholipases C and A2 control lysosome-mediated IL-1{beta} secretion: Implications for inflammatory processes
PNAS, June 29, 2004; 101(26): 9745 - 9750.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
P. J. Hanley, B. Musset, V. Renigunta, S. H. Limberg, A. H. Dalpke, R. Sus, K. M. Heeg, R. Preisig-Muller, and J. Daut
Extracellular ATP induces oscillations of intracellular Ca2+ and membrane potential and promotes transcription of IL-6 in macrophages
PNAS, June 22, 2004; 101(25): 9479 - 9484.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M.-P. Courageot, S. Lepine, M. Hours, F. Giraud, and J.-C. Sulpice
Involvement of Sodium in Early Phosphatidylserine Exposure and Phospholipid Scrambling Induced by P2X7 Purinoceptor Activation in Thymocytes
J. Biol. Chem., May 21, 2004; 279(21): 21815 - 21823.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Inbe, S. Watanabe, M. Miyawaki, E. Tanabe, and J. A. Encinas
Identification and Characterization of a Cell-Surface Receptor, P2Y15, for AMP and Adenosine
J. Biol. Chem., May 7, 2004; 279(19): 19790 - 19799.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Le Stunff, R. Auger, J. Kanellopoulos, and M.-N. Raymond
The Pro-451 to Leu Polymorphism within the C-terminal Tail of P2X7 Receptor Impairs Cell Death but Not Phospholipase D Activation in Murine Thymocytes
J. Biol. Chem., April 23, 2004; 279(17): 16918 - 16926.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Di Virgilio, F.
Right arrow Articles by Baricordi, O. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Di Virgilio, F.
Right arrow Articles by Baricordi, O. R.
Related Collections
Right arrow Hemostasis, Thrombosis, and Vascular Biology
Right arrow Review Articles
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2001 by American Society of Hematology         Online ISSN: 1528-0020